{"b07b79f7d03bce25f7d97ee50ed4c845c4cf20e6": [["As of June 16, 2020, more than 7.5 million cases and more than 400,000 deaths due to COVID-19 have been reported worldwide.", [["deaths", "DISEASE", 71, 77], ["COVID-19", "CHEMICAL", 85, 93], ["COVID", "TEST", 85, 90]]], ["1 In Latin America, Ecuador ranks sixth in absolute number of COVID-19 cases 1 and fourth in per capita rates (281 per 100,000 population) using population data obtained from the World Bank.", [["COVID", "TEST", 62, 67], ["population data", "TEST", 145, 160]]], ["2 These figures, however, are largely believed to be an underestimation of the real spread of SARS-CoV-2, 3 the causative agent of COVID-19.", [["SARS", "DISEASE", 94, 98], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV", "SPECIES", 94, 102], ["CoV", "TEST", 99, 102], ["COVID", "TEST", 131, 136], ["underestimation", "OBSERVATION", 56, 71]]], ["Furthermore, Ecuador has started phasing out containment measures, which may lead to subsequent epidemic peaks.", [["subsequent epidemic peaks", "PROBLEM", 85, 110]]], ["4 Social distancing measures, effective to stop SARS-CoV-2 transmission, 5 have not always been thoroughly followed.", [["SARS", "DISEASE", 48, 52]]], ["Recent reports suggest a loose adoption of social distancing measures in Guayaquil, 6,7 the largest and most affected city of Ecuador.", [["loose", "OBSERVATION_MODIFIER", 25, 30], ["largest", "OBSERVATION_MODIFIER", 92, 99]]], ["The combination of large community spread 1 with improper adoption of social distancing 6 has been of concern to the population.", [["large community spread", "PROBLEM", 19, 41], ["large", "OBSERVATION_MODIFIER", 19, 24], ["community", "OBSERVATION_MODIFIER", 25, 34]]], ["Indeed, mental health issues may arise in the context of the COVID-19 pandemic and its related lockdowns.", [["mental health issues", "PROBLEM", 8, 28], ["the COVID", "TEST", 57, 66]]], ["9 In this scenario, there is need for professionals to provide scientifically proven information that can minimize the risk of contagion and people's anxiety, particularly among high-risk groups such as healthcare workers (HCWs) 10 or those living in areas of intense transmission.", [["anxiety", "DISEASE", 150, 157], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["anxiety", "PROBLEM", 150, 157]]]], "c824bc6203704acb060a33184a503f78835b2f58": [["IntroductionIn 2007, the two new polyomaviruses (PyV) KI and WU were described as probable causative agents of respiratory infections in humans [1, 2] .", [["respiratory", "ANATOMY", 111, 122], ["respiratory infections", "DISEASE", 111, 133], ["polyomaviruses", "ORGANISM", 33, 47], ["humans", "ORGANISM", 137, 143], ["humans", "SPECIES", 137, 143], ["humans", "SPECIES", 137, 143], ["respiratory infections", "PROBLEM", 111, 133], ["respiratory infections", "OBSERVATION", 111, 133]]], ["Currently, they are classified in the Polyomaviridae family, Betapolyomavirus genus, Human polyomavirus 3 (KIPyV), and Human polyomavirus 4 (WUPyV) species [3] .", [["Betapolyomavirus genus", "ORGANISM", 61, 83], ["Human polyomavirus 3", "ORGANISM", 85, 105], ["KIPyV", "GENE_OR_GENE_PRODUCT", 107, 112], ["Human polyomavirus 4", "ORGANISM", 119, 139], ["Human", "SPECIES", 85, 90], ["Human", "SPECIES", 119, 124], ["Human polyomavirus 3", "SPECIES", 85, 105], ["KIPyV", "SPECIES", 107, 112], ["Human polyomavirus 4", "SPECIES", 119, 139], ["WUPyV", "SPECIES", 141, 146], ["Human polyomavirus", "TEST", 85, 103], ["Human polyomavirus", "PROBLEM", 119, 137]]], ["These two PyV have been detected globally in children and immunocompetent adults, with detection rates ranging from 1 to 16.4% for WUPyV and 0.45 to 12.14% for KIPyV [4] [5] [6] [7] [8] .IntroductionThere has been suggested a role for these viruses on the pathogenesis of respiratory infections in many studies so far demonstrating the presence of WUPyV and KIPyV in the respiratory tract of symptomatic and asymptomatic patients [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , although they are also found in other clinical samples such as stool and lymphoid tissue of immunocompromised and immunocompetent individuals [16] [17] [18] [19] [20] .IntroductionCoinfection with other pathogens has been reported in 74% of patients with KIPyV, 68 to 79% of patients with WUPyV, and 10% of coinfection with KIPyV and WUPyV in the absence of other respiratory viruses [21] .", [["respiratory", "ANATOMY", 272, 283], ["respiratory tract", "ANATOMY", 371, 388], ["samples", "ANATOMY", 533, 540], ["stool", "ANATOMY", 549, 554], ["lymphoid tissue", "ANATOMY", 559, 574], ["respiratory infections", "DISEASE", 272, 294], ["KIPyV", "CHEMICAL", 358, 363], ["[4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14", "CHEMICAL", 430, 477], ["Coinfection", "DISEASE", 666, 677], ["KIPyV", "DISEASE", 741, 746], ["WUPyV", "DISEASE", 775, 780], ["coinfection", "DISEASE", 793, 804], ["KIPyV", "CHEMICAL", 810, 815], ["WUPyV", "CHEMICAL", 820, 825], ["respiratory viruses", "DISEASE", 850, 869], ["KIPyV [4] [5] [6] [7]", "CHEMICAL", 160, 181], ["[4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15]", "CHEMICAL", 430, 483], ["PyV", "GENE_OR_GENE_PRODUCT", 10, 13], ["children", "ORGANISM", 45, 53], ["adults", "ORGANISM", 74, 80], ["KIPyV [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 160, 185], ["WUPyV", "GENE_OR_GENE_PRODUCT", 348, 353], ["respiratory tract", "ORGANISM_SUBDIVISION", 371, 388], ["patients", "ORGANISM", 421, 429], ["[4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 430, 483], ["stool", "ORGANISM_SUBSTANCE", 549, 554], ["lymphoid tissue", "TISSUE", 559, 574], ["[17] [18] [19] [20]", "SIMPLE_CHEMICAL", 633, 652], ["patients", "ORGANISM", 727, 735], ["KIPyV", "CANCER", 741, 746], ["patients", "ORGANISM", 761, 769], ["WUPyV", "CANCER", 775, 780], ["PyV", "PROTEIN", 10, 13], ["children", "SPECIES", 45, 53], ["patients", "SPECIES", 421, 429], ["patients", "SPECIES", 727, 735], ["patients", "SPECIES", 761, 769], ["KIPyV", "SPECIES", 810, 815], ["detection rates", "TEST", 87, 102], ["WUPyV", "TEST", 131, 136], ["these viruses", "PROBLEM", 235, 248], ["respiratory infections", "PROBLEM", 272, 294], ["many studies", "TEST", 298, 310], ["WUPyV and KIPyV in the respiratory tract", "PROBLEM", 348, 388], ["immunocompromised", "PROBLEM", 578, 595], ["immunocompetent individuals", "PROBLEM", 600, 627], ["IntroductionCoinfection with other pathogens", "PROBLEM", 654, 698], ["KIPyV", "TEST", 741, 746], ["WUPyV", "TEST", 775, 780], ["coinfection", "PROBLEM", 793, 804], ["KIPyV", "TREATMENT", 810, 815], ["WUPyV", "TREATMENT", 820, 825], ["other respiratory viruses", "PROBLEM", 844, 869], ["globally", "OBSERVATION_MODIFIER", 33, 41], ["respiratory", "ANATOMY", 272, 283], ["infections", "OBSERVATION", 284, 294], ["respiratory tract", "ANATOMY", 371, 388], ["lymphoid tissue", "OBSERVATION", 559, 574], ["Coinfection", "OBSERVATION", 666, 677], ["respiratory viruses", "OBSERVATION", 850, 869]]], ["In Brazil, KIPyV and WUPyV were found in the saliva of immunocompromised and immunocompetent patients [22, 23] .", [["KIPyV", "GENE_OR_GENE_PRODUCT", 11, 16], ["WUPyV", "GENE_OR_GENE_PRODUCT", 21, 26], ["saliva", "ORGANISM_SUBSTANCE", 45, 51], ["patients", "ORGANISM", 93, 101], ["WUPyV", "PROTEIN", 21, 26], ["patients", "SPECIES", 93, 101], ["KIPyV", "TREATMENT", 11, 16], ["WUPyV", "TREATMENT", 21, 26], ["immunocompromised", "OBSERVATION", 55, 72]]], ["In this study, we investigated the PyV KI and WU in the occurence of severe respiratory diseases in hospitalized patients with acute respiratory infection (SARI).Materials and methodsA retrospective study was conducted from April 2009 to November 2010 (19 months) using samples from hospitalized patients who had presented with SARI within 7 days of the onset of symptoms, including fever (> 38.8\u00b0C), dyspnea, and cough.", [["respiratory", "ANATOMY", 76, 87], ["respiratory", "ANATOMY", 133, 144], ["respiratory diseases", "DISEASE", 76, 96], ["acute respiratory infection", "DISEASE", 127, 154], ["SARI", "DISEASE", 156, 160], ["SARI", "DISEASE", 328, 332], ["fever", "DISEASE", 383, 388], ["dyspnea", "DISEASE", 401, 408], ["cough", "DISEASE", 414, 419], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 296, 304], ["this study", "TEST", 3, 13], ["severe respiratory diseases", "PROBLEM", 69, 96], ["acute respiratory infection", "PROBLEM", 127, 154], ["methodsA retrospective study", "TEST", 176, 204], ["SARI", "PROBLEM", 328, 332], ["symptoms", "PROBLEM", 363, 371], ["fever", "PROBLEM", 383, 388], ["dyspnea", "PROBLEM", 401, 408], ["cough", "PROBLEM", 414, 419], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["respiratory diseases", "OBSERVATION", 76, 96], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["respiratory", "ANATOMY", 133, 144], ["infection", "OBSERVATION", 145, 154], ["dyspnea", "OBSERVATION", 401, 408], ["cough", "OBSERVATION", 414, 419]]], ["Children (< 12 years) and adults were included.", [["Children", "ORGANISM", 0, 8], ["adults", "ORGANISM", 26, 32], ["Children", "SPECIES", 0, 8]]], ["Informed consent was previously obtained from all enrolled patients initially suspected to have influenza A(H1N1)pdm09 infections.", [["influenza A(H1N1)pdm09 infections", "DISEASE", 96, 129], ["patients", "ORGANISM", 59, 67], ["influenza A(H1N1)pdm09", "ORGANISM", 96, 118], ["patients", "SPECIES", 59, 67], ["influenza A(H1N1)pdm09 infections", "PROBLEM", 96, 129]]], ["This study was approved by the Ethics Committee of Sao Paulo Federal University (CEP 0090/2016).", [["This study", "TEST", 0, 10]]], ["Nasopharyngeal aspirates were obtained from children under 2 years old.", [["Nasopharyngeal aspirates", "ANATOMY", 0, 24], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 0, 24], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["Nasopharyngeal aspirates", "TEST", 0, 24], ["aspirates", "OBSERVATION", 15, 24]]], ["For the other patients, naso-and oropharyngeal swabs were collected, according to the Brazilian Ministry of Health Protocol for management of influenza A (H1N1) 2009 pandemics, and stored in a freezer at \u2212 80\u00b0C [24] .", [["oropharyngeal swabs", "ANATOMY", 33, 52], ["influenza A (H1N1) 2009 pandemics", "DISEASE", 142, 175], ["patients", "ORGANISM", 14, 22], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 33, 52], ["influenza A", "ORGANISM", 142, 153], ["patients", "SPECIES", 14, 22], ["naso", "TEST", 24, 28], ["oropharyngeal swabs", "TEST", 33, 52], ["Health Protocol", "TREATMENT", 108, 123], ["management", "TREATMENT", 128, 138], ["influenza", "PROBLEM", 142, 151], ["oropharyngeal", "ANATOMY", 33, 46]]], ["Total nucleic acids were extracted using the QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturer instructions.", [["nucleic acids", "CHEMICAL", 6, 19], ["Total nucleic acids", "TREATMENT", 0, 19]]], ["The specimens were then tested for the presence of respiratory viruses according to PCR protocols available at our laboratory for influenza A (FLU A) and B (FLU B) viruses [25, 26] , human respiratory syncytial virus (HRSV) [27] , human rhinovirus (HRV) [28] , human metapneumovirus (hMPV) [29] , human coronavirus (HCoV) [30] , human adenovirus (HAdV) [31, 32] , and parainfluenza virus (PIV 1,2,3,4) [33, 34] .Materials and methodsFor the WUPyV and KIPyV specific detection, qualitative real-time PCR was performed with the primers PyVF (5'-TTGGATGAAAATGGCATTGG-3\u2032) and PyVR (5'-TAACCCTTCTTTGTCTAAARTGTAGCC-3\u2032), that amplify a fragment of the gene encoding the capsid protein VP1 only common to KIPyV and WUPyV, and two specific probes, WUPyVp (5'-FAM-CATAACTTGTGCTGACCTTT TGGGAGTTAAC-BHQ1-3\u2032) and KIPyVp (3'-VIC-ACATTACTTGTGCAGATATGCTTGGAACAGC-BHQ1-3\u2032), both within the VP1 gene, to differentiate the WUPyV and KIPyV viruses [35] .", [["specimens", "ANATOMY", 4, 13], ["respiratory viruses", "DISEASE", 51, 70], ["influenza A", "DISEASE", 130, 141], ["FLU", "CHEMICAL", 143, 146], ["FLU", "CHEMICAL", 157, 160], ["respiratory syncytial virus", "DISEASE", 189, 216], ["human rhinovirus (HRV)", "DISEASE", 231, 253], ["human metapneumovirus (hMPV)", "DISEASE", 261, 289], ["human coronavirus", "DISEASE", 297, 314], ["parainfluenza virus", "DISEASE", 368, 387], ["specimens", "CANCER", 4, 13], ["influenza A", "ORGANISM", 130, 141], ["FLU A", "ORGANISM", 143, 148], ["B (FLU B) viruses", "ORGANISM", 154, 171], ["human", "ORGANISM", 183, 188], ["respiratory syncytial virus", "ORGANISM", 189, 216], ["HRSV", "ORGANISM", 218, 222], ["human", "ORGANISM", 231, 236], ["rhinovirus (HRV", "ORGANISM", 237, 252], ["human", "ORGANISM", 261, 266], ["metapneumovirus", "ORGANISM", 267, 282], ["hMPV", "ORGANISM", 284, 288], ["human coronavirus", "ORGANISM", 297, 314], ["HCoV) [30", "ORGANISM", 316, 325], ["human", "ORGANISM", 329, 334], ["adenovirus", "ORGANISM", 335, 345], ["HAdV", "ORGANISM", 347, 351], ["parainfluenza virus", "ORGANISM", 368, 387], ["VP1", "GENE_OR_GENE_PRODUCT", 678, 681], ["KIPyV", "GENE_OR_GENE_PRODUCT", 697, 702], ["WUPyV", "GENE_OR_GENE_PRODUCT", 707, 712], ["VP1", "GENE_OR_GENE_PRODUCT", 873, 876], ["WUPyV", "GENE_OR_GENE_PRODUCT", 904, 909], ["primers PyVF", "DNA", 526, 538], ["capsid protein VP1", "PROTEIN", 663, 681], ["KIPyV", "PROTEIN", 697, 702], ["WUPyV", "PROTEIN", 707, 712], ["BHQ1", "DNA", 847, 851], ["VP1 gene", "DNA", 873, 881], ["human", "SPECIES", 183, 188], ["respiratory syncytial virus", "SPECIES", 189, 216], ["HRSV", "SPECIES", 218, 222], ["human", "SPECIES", 231, 236], ["rhinovirus", "SPECIES", 237, 247], ["human", "SPECIES", 261, 266], ["metapneumovirus", "SPECIES", 267, 282], ["hMPV", "SPECIES", 284, 288], ["human", "SPECIES", 297, 302], ["coronavirus", "SPECIES", 303, 314], ["human", "SPECIES", 329, 334], ["parainfluenza virus", "SPECIES", 368, 387], ["influenza A", "SPECIES", 130, 141], ["human respiratory syncytial virus", "SPECIES", 183, 216], ["HRSV", "SPECIES", 218, 222], ["human rhinovirus", "SPECIES", 231, 247], ["HRV", "SPECIES", 249, 252], ["human metapneumovirus", "SPECIES", 261, 282], ["hMPV", "SPECIES", 284, 288], ["human coronavirus", "SPECIES", 297, 314], ["HCoV", "SPECIES", 316, 320], ["human adenovirus", "SPECIES", 329, 345], ["HAdV", "SPECIES", 347, 351], ["parainfluenza virus", "SPECIES", 368, 387], ["The specimens", "TEST", 0, 13], ["respiratory viruses", "PROBLEM", 51, 70], ["PCR protocols", "TEST", 84, 97], ["influenza", "PROBLEM", 130, 139], ["B (FLU B) viruses", "TEST", 154, 171], ["human respiratory syncytial virus", "TEST", 183, 216], ["HRSV", "TEST", 218, 222], ["human rhinovirus (HRV)", "TEST", 231, 253], ["human metapneumovirus (hMPV)", "TEST", 261, 289], ["human coronavirus (HCoV)", "TEST", 297, 321], ["human adenovirus (HAdV", "TEST", 329, 351], ["parainfluenza virus", "PROBLEM", 368, 387], ["PIV", "TEST", 389, 392], ["the WUPyV", "TEST", 437, 446], ["KIPyV specific detection", "TEST", 451, 475], ["qualitative real-time PCR", "TEST", 477, 502], ["the primers PyVF", "TREATMENT", 522, 538], ["TTGGATGAAAATGGCATTGG", "TEST", 543, 563], ["PyVR", "TREATMENT", 572, 576], ["the capsid protein VP1", "TREATMENT", 659, 681], ["KIPyV", "TEST", 697, 702], ["WUPyV", "TEST", 707, 712], ["WUPyVp", "TEST", 739, 745], ["TGGGAGTTAAC", "TEST", 775, 786], ["KIPyVp", "TREATMENT", 800, 806], ["VIC-ACATTACTTGTGCAGATATGCTTGGAACAGC", "TEST", 811, 846], ["respiratory viruses", "OBSERVATION", 51, 70], ["respiratory syncytial", "ANATOMY", 189, 210], ["parainfluenza virus", "OBSERVATION", 368, 387]]], ["The concentration of primers and probes was 800 nM and 200 nM, respectively, in 25 \u03bcL of total reaction volume, with the use of AgPath-ID\u2122 One-Step RT-PCR reagents (Applied Biosystems, Austin, USA) and addition of 5 \u03bcL of extracted nucleic acid.", [["nucleic acid", "CHEMICAL", 232, 244], ["nucleic acid", "SIMPLE_CHEMICAL", 232, 244], ["The concentration of primers", "TREATMENT", 0, 28], ["total reaction volume", "TREATMENT", 89, 110], ["PCR reagents", "TREATMENT", 151, 163], ["extracted nucleic acid", "TREATMENT", 222, 244]]], ["In parallel reactions, primers and specific probe were used to amplify a fragment of the gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous control and to assess the quality of the samples as described by Bergallo et al. [16] Thermocycling conditions were performed in an Applied Biosystems 7500 Real-Time PCR System and involved 10 min at 95\u00b0C followed by 45 cycles of 10 s at 95\u00b0C and 1 min at 55\u00b0C (data collection).", [["samples", "ANATOMY", 198, 205], ["glyceraldehyde 3-phosphate", "CHEMICAL", 94, 120], ["glyceraldehyde 3-phosphate", "CHEMICAL", 94, 120], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 94, 134], ["GAPDH", "GENE_OR_GENE_PRODUCT", 136, 141], ["glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 94, 134], ["GAPDH", "PROTEIN", 136, 141], ["parallel reactions", "PROBLEM", 3, 21], ["primers", "TREATMENT", 23, 30], ["specific probe", "TREATMENT", 35, 49], ["the gene glyceraldehyde", "TREATMENT", 85, 108], ["phosphate dehydrogenase (GAPDH)", "TREATMENT", 111, 142], ["endogenous control", "TREATMENT", 146, 164]]], ["For both reactions, the cycle threshold value (Ct) of 39 was adopted as a cut-off.", [["both reactions", "PROBLEM", 4, 18], ["the cycle threshold value", "TEST", 20, 45], ["Ct", "TEST", 47, 49]]], ["Chi-square analysis and Fisher's exact test were used to analyze the occurrence of the investigated PyV.", [["Chi-square analysis", "TEST", 0, 19], ["Fisher's exact test", "TEST", 24, 43]]], ["Student's t test for independent samples and analysis of variance (ANOVA) were used to compare the mean ages.", [["Student's t test", "TEST", 0, 16], ["independent samples", "TEST", 21, 40], ["analysis of variance (ANOVA)", "TEST", 45, 73]]], ["All statistical analyses were performed using OpenEpi version 2.3.1 (http://www.openepi.com), and a p value < 0.05 was considered statistically significant.", [["All statistical analyses", "TEST", 0, 24], ["OpenEpi version", "TEST", 46, 61], ["a p value", "TEST", 98, 107]]], ["Table 1 compares the viral detection patterns within the 251 patients included in the study.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["the viral detection patterns", "TEST", 17, 45], ["the study", "TEST", 82, 91]]], ["Among the patients with viral infection, 18.5% (29/157) had a coinfection with 2 different viruses and 6.4% (10/157) with 3.", [["viral infection", "DISEASE", 24, 39], ["coinfection", "DISEASE", 62, 73], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["viral infection", "PROBLEM", 24, 39], ["a coinfection", "PROBLEM", 60, 73], ["2 different viruses", "PROBLEM", 79, 98], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39], ["coinfection", "OBSERVATION", 62, 73]]], ["Of the population with double viral coinfections, 44.8% (13/29) were also infected with WUPyVor KIPyV and 4 out of the 10 patients with triple coinfections were also positive for WUPyV or KIPyV.", [["viral coinfections", "DISEASE", 30, 48], ["coinfections", "DISEASE", 143, 155], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["WUPyV", "SPECIES", 179, 184], ["double viral coinfections", "PROBLEM", 23, 48], ["triple coinfections", "PROBLEM", 136, 155], ["KIPyV", "TREATMENT", 188, 193], ["population", "OBSERVATION_MODIFIER", 7, 17], ["double", "OBSERVATION_MODIFIER", 23, 29], ["viral coinfections", "OBSERVATION", 30, 48]]], ["However, coinfection with WUPyV or KIPyV and other viruses was not correlated with severity of symptoms.ResultsThe proportion of children with WUPyV or KIPyV was 7.3% (11/150), and all samples had multiple detections.", [["samples", "ANATOMY", 185, 192], ["coinfection", "DISEASE", 9, 20], ["WUPyV", "GENE_OR_GENE_PRODUCT", 26, 31], ["KIPyV", "GENE_OR_GENE_PRODUCT", 35, 40], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["WUPyV", "SPECIES", 26, 31], ["coinfection", "PROBLEM", 9, 20], ["WUPyV", "TREATMENT", 26, 31], ["KIPyV", "TREATMENT", 35, 40], ["other viruses", "PROBLEM", 45, 58], ["symptoms", "PROBLEM", 95, 103], ["KIPyV", "TEST", 152, 157], ["all samples", "TEST", 181, 192], ["multiple detections", "TEST", 197, 216], ["coinfection", "OBSERVATION", 9, 20], ["viruses", "OBSERVATION", 51, 58]]], ["The mean age of the children coinfected with polyomaviruses was 1.6 years (median 1 year; range 0-4 years); of these 7 had WUPyV infection and 4 had KIPyV infection.", [["infection", "DISEASE", 129, 138], ["infection", "DISEASE", 155, 164], ["children", "ORGANISM", 20, 28], ["polyomaviruses", "ORGANISM", 45, 59], ["children", "SPECIES", 20, 28], ["WUPyV", "SPECIES", 123, 128], ["WUPyV infection", "PROBLEM", 123, 138], ["KIPyV infection", "PROBLEM", 149, 164], ["infection", "OBSERVATION", 129, 138], ["infection", "OBSERVATION", 155, 164]]], ["The children coinfected with respiratory viruses other than PyV were younger than those coinfected with PyV, with rates among patients up to 6 months of age being 1/11 (9.1%) and 12/24 (50.0%), respectively (p < 0.027).ResultsTwo adults (aged 33 and 91 years) showed coinfections with WUPyV or KIPyV, respectively.", [["respiratory viruses", "DISEASE", 29, 48], ["coinfections", "DISEASE", 267, 279], ["children", "ORGANISM", 4, 12], ["patients", "ORGANISM", 126, 134], ["adults", "ORGANISM", 230, 236], ["children", "SPECIES", 4, 12], ["patients", "SPECIES", 126, 134], ["respiratory viruses", "PROBLEM", 29, 48], ["coinfections", "PROBLEM", 267, 279], ["coinfections", "OBSERVATION", 267, 279]]], ["Monoinfections were detected in 4 adults, and 3 of them had WUPyV infection (median age 30 years, range 21-51 years).", [["Monoinfections", "DISEASE", 0, 14], ["WUPyV infection", "DISEASE", 60, 75], ["WUPyV", "SPECIES", 60, 65], ["Monoinfections", "TEST", 0, 14], ["WUPyV infection", "PROBLEM", 60, 75], ["infection", "OBSERVATION", 66, 75]]], ["These 4 patients were admitted with fever, cough, and dyspnea, and the symptoms prevailed for up to 4 days.", [["fever", "DISEASE", 36, 41], ["cough", "DISEASE", 43, 48], ["dyspnea", "DISEASE", 54, 61], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["fever", "PROBLEM", 36, 41], ["cough", "PROBLEM", 43, 48], ["dyspnea", "PROBLEM", 54, 61], ["the symptoms", "PROBLEM", 67, 79], ["cough", "OBSERVATION", 43, 48]]], ["Radiological chest examination, bacterial hemoculture and systemic antibiotic prophylaxis were conducted according to hospital proceedings for clinical bacterial pneumonia investigation and current guidelines.", [["chest", "ANATOMY", 13, 18], ["pneumonia", "DISEASE", 162, 171], ["Radiological chest examination", "TEST", 0, 30], ["bacterial hemoculture", "TEST", 32, 53], ["systemic antibiotic prophylaxis", "TREATMENT", 58, 89], ["clinical bacterial pneumonia investigation", "PROBLEM", 143, 185], ["chest", "ANATOMY", 13, 18], ["pneumonia", "OBSERVATION", 162, 171]]], ["Three patients reported comorbidities and presented with different states of immunosuppression.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["comorbidities", "PROBLEM", 24, 37], ["immunosuppression", "TREATMENT", 77, 94], ["immunosuppression", "OBSERVATION", 77, 94]]], ["The length of the period of hospitalization and ICU admission are shown in Table 2 .", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The patient with systemic lupus erythematosus (SLE) was admitted to the ICU for mechanical ventilation due to nosocomial pneumonia with bacterial coinfection.", [["systemic lupus erythematosus", "DISEASE", 17, 45], ["SLE", "DISEASE", 47, 50], ["pneumonia", "DISEASE", 121, 130], ["bacterial coinfection", "DISEASE", 136, 157], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["systemic lupus erythematosus", "PROBLEM", 17, 45], ["mechanical ventilation", "TREATMENT", 80, 102], ["nosocomial pneumonia", "PROBLEM", 110, 130], ["bacterial coinfection", "PROBLEM", 136, 157], ["systemic", "OBSERVATION_MODIFIER", 17, 25], ["lupus erythematosus", "OBSERVATION", 26, 45], ["nosocomial", "OBSERVATION_MODIFIER", 110, 120], ["pneumonia", "OBSERVATION", 121, 130], ["bacterial coinfection", "OBSERVATION", 136, 157]]], ["The 28-year-old patient without comorbidities was hospitalized for 24 h and was discharged upon resolution of the dyspnea.DiscussionThe role of the PyV in the pathogenesis of respiratory infections is not well understood.", [["respiratory", "ANATOMY", 175, 186], ["dyspnea", "DISEASE", 114, 121], ["respiratory infections", "DISEASE", 175, 197], ["patient", "ORGANISM", 16, 23], ["PyV", "GENE_OR_GENE_PRODUCT", 148, 151], ["PyV", "DNA", 148, 151], ["patient", "SPECIES", 16, 23], ["comorbidities", "PROBLEM", 32, 45], ["the dyspnea", "PROBLEM", 110, 121], ["respiratory infections", "PROBLEM", 175, 197], ["dyspnea", "OBSERVATION", 114, 121], ["respiratory", "ANATOMY", 175, 186], ["infections", "OBSERVATION", 187, 197]]], ["Some studies have demonstrated the presence of both PyV WU and KI in the asymptomatic population [36, 37] .", [["Some studies", "TEST", 0, 12]]], ["However, the rate of polyomavirus infection in adult patients hospitalized with SARI has not been established.DiscussionThe proportion of respiratory samples from hospitalized patients with SARI that were positive for WUPyV or KIPyV was 6.8% with 4.0% (10/251) for WUPyV and 2.8% (7/251) for KIPyV, which is comparable to those obtained by other authors [4] [5] [6] [7] 11] .DiscussionThe debate about the role of these viruses in respiratory infections is ongoing because of the high rates of coinfection with other respiratory viruses (approximately 80%) [9, 11, 12, 38, 39] .", [["respiratory samples", "ANATOMY", 138, 157], ["respiratory", "ANATOMY", 431, 442], ["polyomavirus infection", "DISEASE", 21, 43], ["SARI", "DISEASE", 80, 84], ["respiratory infections", "DISEASE", 431, 453], ["coinfection", "DISEASE", 494, 505], ["respiratory viruses", "DISEASE", 517, 536], ["polyomavirus", "ORGANISM", 21, 33], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 176, 184], ["[4] [5] [6] [7] 11", "SIMPLE_CHEMICAL", 354, 372], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 176, 184], ["polyomavirus infection", "PROBLEM", 21, 43], ["SARI", "PROBLEM", 80, 84], ["SARI", "PROBLEM", 190, 194], ["WUPyV", "TEST", 218, 223], ["KIPyV", "TEST", 227, 232], ["WUPyV", "TEST", 265, 270], ["KIPyV", "TEST", 292, 297], ["these viruses", "PROBLEM", 414, 427], ["respiratory infections", "PROBLEM", 431, 453], ["coinfection", "PROBLEM", 494, 505], ["other respiratory viruses", "PROBLEM", 511, 536], ["polyomavirus", "OBSERVATION_MODIFIER", 21, 33], ["infection", "OBSERVATION", 34, 43], ["respiratory", "ANATOMY", 138, 149], ["viruses", "OBSERVATION", 420, 427], ["respiratory", "ANATOMY", 431, 442], ["infections", "OBSERVATION", 443, 453], ["coinfection", "OBSERVATION", 494, 505], ["respiratory viruses", "OBSERVATION", 517, 536]]], ["Recently, high viral loads of KIPyV were observed in children with severe or very severe pneumonia in the absence of other viral or bacterial respiratory infection, suggesting a potential pathogenic role for KIPyV in these patients [12] .DiscussionA coinfection rate of 76.5% was observed in the present study, mainly among children, with the most common types being WUPyV/HRV in 43% of cases, KIPyV/HRV in 60% and KIPyV/AdV in 67%, which is in accordance with the results by Allander et al. [1] and Gaynor et al. [2] Nonetheless, the frequent coinfections with WUPyV and KIPyV with other respiratory viruses and variations in clinical presentation preclude any conclusion about the association between infection and disease in children.", [["respiratory", "ANATOMY", 142, 153], ["pneumonia", "DISEASE", 89, 98], ["respiratory infection", "DISEASE", 142, 163], ["KIPyV", "CHEMICAL", 208, 213], ["coinfections", "DISEASE", 544, 556], ["respiratory viruses", "DISEASE", 589, 608], ["infection", "DISEASE", 703, 712], ["KIPyV", "GENE_OR_GENE_PRODUCT", 30, 35], ["children", "ORGANISM", 53, 61], ["KIPyV", "SIMPLE_CHEMICAL", 208, 213], ["patients", "ORGANISM", 223, 231], ["children", "ORGANISM", 324, 332], ["children", "ORGANISM", 728, 736], ["children", "SPECIES", 53, 61], ["patients", "SPECIES", 223, 231], ["children", "SPECIES", 324, 332], ["children", "SPECIES", 728, 736], ["KIPyV/AdV", "SPECIES", 415, 424], ["high viral loads of KIPyV", "PROBLEM", 10, 35], ["very severe pneumonia", "PROBLEM", 77, 98], ["other viral or bacterial respiratory infection", "PROBLEM", 117, 163], ["DiscussionA coinfection rate", "TEST", 238, 266], ["KIPyV", "TREATMENT", 394, 399], ["HRV", "TEST", 400, 403], ["KIPyV/AdV", "TREATMENT", 415, 424], ["the frequent coinfections", "PROBLEM", 531, 556], ["WUPyV", "TREATMENT", 562, 567], ["KIPyV", "TREATMENT", 572, 577], ["other respiratory viruses", "PROBLEM", 583, 608], ["infection", "PROBLEM", 703, 712], ["disease", "PROBLEM", 717, 724], ["high", "OBSERVATION_MODIFIER", 10, 14], ["viral loads", "OBSERVATION", 15, 26], ["very", "OBSERVATION_MODIFIER", 77, 81], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["pneumonia", "OBSERVATION", 89, 98], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["bacterial", "OBSERVATION_MODIFIER", 132, 141], ["respiratory infection", "OBSERVATION", 142, 163], ["frequent", "OBSERVATION_MODIFIER", 535, 543], ["coinfections", "OBSERVATION", 544, 556], ["respiratory", "ANATOMY", 589, 600], ["viruses", "OBSERVATION", 601, 608], ["infection", "OBSERVATION", 703, 712]]], ["Of interest is the finding of lower rates among very young children that may posit the later acquisition of polyomavirus infection by older children as suggest by serological and molecular studies [19, [40] [41] [42] .DiscussionThe finding of monoinfection by polyomaviruses in 4 adult patients hospitalized with SARI may suggest a potential pathogenic role.", [["polyomavirus infection", "DISEASE", 108, 130], ["monoinfection", "DISEASE", 243, 256], ["SARI", "DISEASE", 313, 317], ["children", "ORGANISM", 59, 67], ["polyomavirus", "ORGANISM", 108, 120], ["children", "ORGANISM", 140, 148], ["polyomaviruses", "ORGANISM", 260, 274], ["patients", "ORGANISM", 286, 294], ["children", "SPECIES", 59, 67], ["children", "SPECIES", 140, 148], ["patients", "SPECIES", 286, 294], ["polyomavirus infection", "PROBLEM", 108, 130], ["serological and molecular studies", "TEST", 163, 196], ["monoinfection", "PROBLEM", 243, 256], ["polyomaviruses", "PROBLEM", 260, 274], ["SARI", "PROBLEM", 313, 317], ["monoinfection", "OBSERVATION", 243, 256], ["polyomaviruses", "OBSERVATION", 260, 274]]], ["Moreover, 3 out of these 4 patients were immunocompromised, and one patient with SLE had a severe outcome and required ICU admission and mechanical ventilation.", [["SLE", "DISEASE", 81, 84], ["patients", "ORGANISM", 27, 35], ["patient", "ORGANISM", 68, 75], ["patients", "SPECIES", 27, 35], ["patient", "SPECIES", 68, 75], ["immunocompromised", "PROBLEM", 41, 58], ["a severe outcome", "PROBLEM", 89, 105], ["ICU admission", "TREATMENT", 119, 132], ["mechanical ventilation", "TREATMENT", 137, 159], ["immunocompromised", "OBSERVATION", 41, 58], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["mechanical ventilation", "OBSERVATION", 137, 159]]], ["We performed a retrospective study.", [["a retrospective study", "TEST", 13, 34]]], ["Therefore, it was not possible to obtain samples from the lower respiratory tract from the immunocompromised patients for immunohistochemistry or in situ hybridization.", [["samples", "ANATOMY", 41, 48], ["lower respiratory tract", "ANATOMY", 58, 81], ["lower respiratory", "ORGANISM_SUBDIVISION", 58, 75], ["tract", "ORGANISM_SUBDIVISION", 76, 81], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["the lower respiratory tract", "PROBLEM", 54, 81], ["immunohistochemistry", "TEST", 122, 142], ["lower", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81]]], ["Further studies are needed in order to understand the possible role of viral latency and reactivation of these DNA viruses in adult patients, especially among those who are immunocompromised.", [["DNA", "CELLULAR_COMPONENT", 111, 114], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["Further studies", "TEST", 0, 15], ["viral latency", "PROBLEM", 71, 84], ["these DNA viruses", "PROBLEM", 105, 122], ["immunocompromised", "PROBLEM", 173, 190], ["viral latency", "OBSERVATION", 71, 84], ["immunocompromised", "OBSERVATION", 173, 190]]], ["In this regard, prospective longitudinal studies with large sample sizes, including immunocompetent, immunocompromised, symptomatic, and asymptomatic patients could better answer some of these questions.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["prospective longitudinal studies", "TEST", 16, 48], ["large sample sizes", "PROBLEM", 54, 72], ["immunocompetent", "PROBLEM", 84, 99], ["immunocompromised", "PROBLEM", 101, 118], ["symptomatic", "PROBLEM", 120, 131], ["large", "OBSERVATION_MODIFIER", 54, 59], ["sizes", "OBSERVATION_MODIFIER", 67, 72], ["immunocompetent", "OBSERVATION_MODIFIER", 84, 99], ["immunocompromised", "OBSERVATION", 101, 118]]]], "PMC2935601": [["IntroductionThe recent outbreaks of SARS coronavirus and avian and swine influenza strains have highlighted the importance of pathogen cross-species transmission, and subsequent evolutionary adaption, in the emergence of new diseases (Woolhouse et al. 2005; Dennehy 2009).", [["SARS coronavirus", "DISEASE", 36, 52], ["influenza", "DISEASE", 73, 82], ["SARS coronavirus", "ORGANISM", 36, 52], ["avian", "ORGANISM", 57, 62], ["swine influenza strains", "ORGANISM", 67, 90], ["coronavirus", "SPECIES", 41, 52], ["avian", "SPECIES", 57, 62], ["swine influenza", "SPECIES", 67, 82], ["SARS coronavirus", "SPECIES", 36, 52], ["SARS coronavirus", "PROBLEM", 36, 52], ["avian", "TREATMENT", 57, 62], ["swine influenza strains", "PROBLEM", 67, 90], ["new diseases", "PROBLEM", 221, 233]]], ["Such \u2018species jumps\u2019 have been proposed as a major source of novel pathogen introductions (Woolhouse et al. 2005; Day et al. 2006; Kuiken et al. 2006), and indeed many emerging human diseases are zoonotic (Cleaveland et al. 2001; Taylor et al. 2001).", [["human diseases", "DISEASE", 177, 191], ["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["Such \u2018species jumps", "PROBLEM", 0, 19]]], ["Typically, these pathogens are initially poorly adapted to humans because of physiological differences between species (Kuiken et al. 2006).", [["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["these pathogens", "PROBLEM", 11, 26], ["physiological differences between species", "PROBLEM", 77, 118], ["pathogens", "OBSERVATION", 17, 26]]], ["Thus, significant spread of these pathogens within the human population often requires evolutionary adaptation (Dennehy 2009).IntroductionA number of risk factors have been proposed to explain why some pathogens emerge and others do not.", [["human", "ORGANISM", 55, 60], ["risk factors", "PROTEIN", 150, 162], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["these pathogens", "PROBLEM", 28, 43], ["risk factors", "PROBLEM", 150, 162], ["some pathogens", "PROBLEM", 197, 211], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["pathogens", "OBSERVATION", 34, 43]]], ["These include the breadth of the pathogen's host range (Cleaveland et al. 2001; Taylor et al. 2001; Woolhouse & Gaunt 2007), susceptibility of the host (Woolhouse et al. 2005; Woolhouse & Gaunt 2007), contact patterns in the host population (Woolhouse et al. 2005; Kuiken et al. 2006; Woolhouse & Gaunt 2007; Dennehy 2009), the mechanism(s) of pathogen adaptation (e.g. whether recombination is possible; Woolhouse et al. 2005), pathogen taxonomic classification (Cleaveland et al. 2001; Taylor et al. 2001), pathogen generation time (Cleaveland et al. 2001; Taylor et al. 2001) or growth rate (Dennehy 2009) and pathogen mutability (Cleaveland et al. 2001; Taylor et al. 2001; Woolhouse et al. 2005; Dennehy 2009).", [["growth rate", "TEST", 582, 593], ["pathogen mutability", "PROBLEM", 613, 632]]], ["Indeed, empirical studies have revealed that some of these factors are often associated with emerging diseases (Cleaveland et al. 2001; Taylor et al. 2001; Woolhouse & Gaunt 2007).", [["empirical studies", "TEST", 8, 25], ["emerging diseases", "PROBLEM", 93, 110]]], ["In particular, viruses and protozoa display a relatively high propensity for being involved in newly emerging human diseases (Cleaveland et al. 2001; Taylor et al. 2001), and the degree of transmissibility between members of the new host species also appears to be a risk factor where data are available (Taylor et al. 2001).IntroductionThe association between transmissibility and likelihood of emergence is, perhaps, not surprising.", [["human diseases", "DISEASE", 110, 124], ["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["viruses and protozoa", "PROBLEM", 15, 35], ["newly emerging human diseases", "PROBLEM", 95, 124], ["viruses", "OBSERVATION", 15, 22], ["relatively", "OBSERVATION_MODIFIER", 46, 56], ["high propensity", "OBSERVATION_MODIFIER", 57, 72]]], ["Any factor that increases the expected number of transmitted infections, such as higher initial transmissibility between members of the new host species, means that the pathogen can circulate for longer after the cross-species jump, and thus has greater potential for ultimate evolutionary adaptation (Antia et al. 2003).", [["infections", "DISEASE", 61, 71], ["Any factor", "PROBLEM", 0, 10], ["transmitted infections", "PROBLEM", 49, 71], ["the pathogen", "PROBLEM", 165, 177], ["infections", "OBSERVATION", 61, 71]]], ["For the same reason, patterns of contact among hosts should also play an important role in disease emergence, because some contact structures ought to lead to greater scope for transmission than others.", [["some contact structures", "PROBLEM", 118, 141]]], ["To date, however, the most \u2018risky\u2019 patterns of host contact are not known.IntroductionThe association between pathogen taxonomic classification and likelihood of emergence is less easy to explain.", [["taxonomic classification", "OBSERVATION", 119, 143]]], ["It has been suggested that the high incidence of emergence among viruses may be attributed, at least partially, to their high mutation rates (particularly in RNA viruses).", [["emergence among viruses", "PROBLEM", 49, 72], ["their high mutation rates", "PROBLEM", 115, 140], ["high", "OBSERVATION_MODIFIER", 31, 35]]], ["A high mutation rate might lead to a greater likelihood of the appropriate adaptive mutations occurring, implying greater evolutionary potential (Cleaveland et al. 2001; Woolhouse et al. 2005).", [["A high mutation rate", "PROBLEM", 0, 20], ["the appropriate adaptive mutations", "PROBLEM", 59, 93], ["high mutation", "OBSERVATION", 2, 15]]], ["On the other hand, most mutations are deleterious, and a high mutation rate could thereby increase the chance of pathogen extinction (Dennehy 2009).", [["a high mutation rate", "PROBLEM", 55, 75], ["pathogen extinction", "PROBLEM", 113, 132], ["deleterious", "OBSERVATION", 38, 49], ["pathogen extinction", "OBSERVATION", 113, 132]]], ["Indeed, this propensity for extinction might be exploited clinically by drug-induced \u2018lethal mutagenesis\u2019 (Anderson et al. 2004; Clementi 2008).", [["extinction", "PROBLEM", 28, 38]]], ["Thus, it remains unclear whether higher mutation rates do indeed lead to a higher likelihood of evolutionary emergence, or whether other processes are required to explain the empirical patterns.IntroductionIn this paper, we investigate the above factors through mathematical modelling.", [["higher mutation rates", "PROBLEM", 33, 54]]], ["We ask two main questions: (i) what types of host contact structure lead to the greatest risk of evolutionary emergence? and (ii) how do patterns of mutation affect the risk of evolutionary emergence?", [["mutation affect", "PROBLEM", 149, 164], ["evolutionary emergence", "PROBLEM", 177, 199]]], ["We address these questions using a branching process model that tracks the number of infected hosts as a newly introduced pathogen spreads and evolves.", [["a branching process model", "TREATMENT", 33, 58], ["infected hosts", "PROBLEM", 85, 99], ["a newly introduced pathogen spreads", "PROBLEM", 103, 138], ["infected", "OBSERVATION", 85, 93]]], ["There have been two main approaches to using such models in the epidemiological literature, a network-based approach and a phenomenological approach.", [["a network-based approach", "TREATMENT", 92, 116], ["a phenomenological approach", "TREATMENT", 121, 148], ["two", "OBSERVATION_MODIFIER", 16, 19], ["main", "OBSERVATION_MODIFIER", 20, 24]]], ["In order to address the above questions, we place these two approaches within a common framework, generalizing to allow for arbitrary contact patterns and arbitrary pathways of evolutionary adaptation.Single-strain models ::: A unified modelling frameworkWe model in discrete time, using a Galton\u2013Watson process.", [["a Galton\u2013Watson process", "TREATMENT", 288, 311], ["discrete", "OBSERVATION_MODIFIER", 267, 275]]], ["To define the branching process, we require a distribution for the number of \u2018offspring\u2019 produced by each individual.", [["branching", "OBSERVATION_MODIFIER", 14, 23], ["process", "OBSERVATION", 24, 31]]], ["In the present context, infected hosts are the individuals of interest, and an \u2018offspring\u2019 is viewed as a contact to whom the infection is transmitted.", [["infection", "DISEASE", 126, 135], ["the infection", "PROBLEM", 122, 135], ["infected", "OBSERVATION", 24, 32], ["infection", "OBSERVATION", 126, 135]]], ["The network-based approach and the phenomenological approach arrive at this offspring distribution in different ways.", [["the phenomenological approach", "TREATMENT", 31, 60]]], ["The phenomenological approach, on the other hand, simply specifies this offspring distribution directly, without explicit consideration of the underlying contact and transmission processes through which it might arise.Single-strain models ::: A unified modelling frameworkThe network-based approach represents the host population by a graph: each vertex or node corresponds to an individual, and an edge between two nodes signifies that the two individuals are acquaintances, i.e. can contact and potentially transmit disease to one another.", [["node", "ANATOMY", 357, 361], ["node", "PROBLEM", 357, 361], ["phenomenological approach", "OBSERVATION", 4, 29], ["node", "OBSERVATION", 357, 361], ["nodes", "OBSERVATION", 416, 421]]], ["We assume that this network is static, and restrict attention to random graphs in the limit of infinite population size.", [["random graphs", "TEST", 65, 78], ["size", "OBSERVATION_MODIFIER", 115, 119]]], ["In this situation, the network becomes a tree graph, with the number of \u2018branches\u2019 from each node drawn independently from the arbitrary degree, or contact, distribution (Trapman 2007 and references therein).", [["node", "ANATOMY", 93, 97], ["tree graph", "OBSERVATION", 41, 51], ["branches", "ANATOMY_MODIFIER", 73, 81], ["node", "OBSERVATION", 93, 97], ["arbitrary degree", "OBSERVATION_MODIFIER", 127, 143]]], ["This restriction is applied for mathematical tractability, but neglects certain realistic network properties such as loops and clustering; we return to this issue in \u00a74.3.", [["This restriction", "TREATMENT", 0, 16], ["mathematical tractability", "PROBLEM", 32, 57]]], ["All individuals infected by a generation n infective (n = 0, 1, \u2026) are considered generation n + 1 infectives, and \u2018later-generation\u2019 infectives (i.e. generation \u2265 1) receive their infections from other individuals within the population.Single-strain models ::: A unified modelling frameworkFollowing the derivation presented by Brauer (2008), we suppose that each node has a degree distribution {pd}, described by the probability generating function (PGF)", [["node", "ANATOMY", 365, 369], ["infectives", "DISEASE", 134, 144], ["infections", "DISEASE", 181, 191], ["node", "MULTI-TISSUE_STRUCTURE", 365, 369], ["All individuals infected", "PROBLEM", 0, 24], ["a generation n infective", "PROBLEM", 28, 52], ["generation n + 1 infectives", "PROBLEM", 82, 109], ["their infections", "PROBLEM", 175, 191], ["infected", "OBSERVATION", 16, 24], ["infections", "OBSERVATION", 181, 191], ["node", "OBSERVATION", 365, 369]]]], "PMC7324229": [["Nominals, and the satisfaction operators they give rise to, make hybrid logic well-suited for different applications ranging from temporal logic [4] to epistemic logics for social networks [22].", [["different applications", "TREATMENT", 94, 116]]], ["The description logics underlying the Web Ontology Language and applications in biomedical informatics [16] can also be seen as forms of hybrid logic [2].IntroductionST is a sound and complete tableau system for hybrid logic.", [["hybrid logic", "PROBLEM", 212, 224]]], ["Two completeness proofs exist for ST, a synthetic one that does not cover the rule restrictions [17] and a complex translation-based proof that does [5].", [["ST", "PROBLEM", 34, 36], ["a complex translation", "PROBLEM", 105, 126]]], ["In this paper we modify ST and three of its restrictions slightly, and use the proof assistant Isabelle/HOL to show that we can lift these restrictions by (a) formally proving the admissibility of their unrestricted versions, and (b) formalizing a synthetic completeness proof for the modified calculus.IntroductionIsabelle is a generic proof assistant and Isabelle/HOL is its instance based on higher-order logic [20].", [["calculus", "DISEASE", 294, 302], ["the modified calculus", "PROBLEM", 281, 302], ["Isabelle/HOL", "TREATMENT", 357, 369], ["calculus", "OBSERVATION", 294, 302]]], ["The full formalization, 4396 lines, is available in the Archive of Formal Proofs which keeps refereed submissions up to date with the current Isabelle version [13].", [["4396 lines", "CELL_LINE", 24, 34]]], ["We chose Isabelle/HOL because it is the proof assistant we know best.Syntax and SemanticsThe well-formed formulas of basic hybrid logic are defined as follow.", [["Syntax", "TREATMENT", 69, 75], ["Semantics", "OBSERVATION", 80, 89], ["-formed", "OBSERVATION_MODIFIER", 97, 104]]]], "PMC7439160": [], "a2a391086724c20993fec522863d63007a362744": [["Severe acute respiratory syndrome (SARS), a new infectious disease caused by SARS-CoV, was first recognized in China in [2002] [2003] .", [["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["infectious disease", "DISEASE", 48, 66], ["SARS-CoV", "DISEASE", 77, 85], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "SPECIES", 77, 85], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 35, 39], ["a new infectious disease", "PROBLEM", 42, 66], ["SARS", "PROBLEM", 77, 81], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["new", "OBSERVATION_MODIFIER", 44, 47], ["infectious", "OBSERVATION", 48, 58]]], ["Similar outbreaks occurred in Hong Kong, Singapore and Toronto making them the initial hot zone of SARS.", [["SARS", "DISEASE", 99, 103], ["outbreaks", "OBSERVATION", 8, 17]]], ["According to World Health Organization, the outbreak of SARS epidemic in 2002-2003 infected over 8400 people globally resulting in deaths of over 900 individuals.", [["SARS", "DISEASE", 56, 60], ["deaths", "DISEASE", 131, 137], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["SARS", "PROBLEM", 56, 60]]], ["Coronaviruses are the RNA viruses containing positive-sense single stranded RNA genome of 27-32 kb.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["positive-sense single stranded RNA genome", "DNA", 45, 86], ["Coronaviruses", "PROBLEM", 0, 13], ["the RNA viruses", "TEST", 18, 33], ["RNA viruses", "OBSERVATION", 22, 33]]], ["Analysis of the nucleotide sequences of the novel SARS-CoV showed that the viral genome is nearly 30 kb in length and contains 14 potential open reading frames flanked by 5 and 3 untranslational region.", [["SARS", "DISEASE", 50, 54], ["nucleotide", "CHEMICAL", 16, 26], ["SARS-CoV", "ORGANISM", 50, 58], ["SARS-CoV", "DNA", 50, 58], ["viral genome", "DNA", 75, 87], ["open reading frames", "DNA", 140, 159], ["5 and 3 untranslational region", "DNA", 171, 201], ["SARS-CoV", "SPECIES", 50, 58], ["the nucleotide sequences", "TEST", 12, 36], ["the viral genome", "PROBLEM", 71, 87], ["viral genome", "OBSERVATION", 75, 87], ["30 kb", "OBSERVATION_MODIFIER", 98, 103]]], ["SARS-CoV contains four major structural gene open reading frames including spike (S), membrane (M), envelope (E) and nucleocapsid protein (NP) and a set of accessory proteins whose number and sequence vary among different coronaviruses.", [["membrane", "ANATOMY", 86, 94], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 100, 112], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 117, 137], ["SARS-CoV", "DNA", 0, 8], ["structural gene open reading frames", "DNA", 29, 64], ["spike (S), membrane (M), envelope (E) and nucleocapsid protein", "PROTEIN", 75, 137], ["NP", "PROTEIN", 139, 141], ["accessory proteins", "PROTEIN", 156, 174], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["spike (S), membrane (M), envelope (E", "TEST", 75, 111], ["nucleocapsid protein", "TEST", 117, 137], ["accessory proteins", "PROBLEM", 156, 174], ["different coronaviruses", "PROBLEM", 212, 235]]], ["The continual lack of a rapid sensitive antigen test to assist in the diagnosis of suspected cases and in turn of probable cases of SARS makes this area a pri- * Corresponding author. ority for further research efforts to develop inexpensive point of care rapid diagnostics.", [["SARS", "DISEASE", 132, 136], ["a rapid sensitive antigen test", "PROBLEM", 22, 52], ["SARS", "PROBLEM", 132, 136], ["rapid diagnostics", "TEST", 256, 273]]], ["The three major diagnostic methods that are currently available include viral RNA detection using RT-PCR (Jiang et al., 2004) , detection of antibody by indirect fluorescence assay and NP or culture extract of SARS-CoV-based enzyme linked immunosorbent assay .", [["viral RNA", "RNA", 72, 81], ["SARS-CoV", "SPECIES", 210, 218], ["viral RNA detection", "TEST", 72, 91], ["RT-PCR", "TEST", 98, 104], ["antibody", "TEST", 141, 149], ["indirect fluorescence assay", "TEST", 153, 180], ["NP", "TEST", 185, 187], ["culture extract", "TEST", 191, 206], ["SARS", "PROBLEM", 210, 214], ["CoV", "TEST", 215, 218], ["based enzyme", "TEST", 219, 231], ["immunosorbent assay", "TEST", 239, 258]]]], "a29f89a48ae00d4c88d987e971c6cfa0a8f5a1fe": [["IntroductionThe World Health Organization declared the coronavirus disease 2019 (COVID-19) a pandemic on 11 March 2020 [1] .", [["coronavirus disease", "DISEASE", 55, 74], ["coronavirus", "ORGANISM", 55, 66], ["the coronavirus disease", "PROBLEM", 51, 74], ["COVID", "TEST", 81, 86], ["coronavirus disease", "OBSERVATION", 55, 74]]], ["Given the nature of this global public health emergency, multiple drugs have been tried in the battle against this disease.", [["multiple drugs", "TREATMENT", 57, 71], ["this disease", "PROBLEM", 110, 122]]], ["Some of these include antimalarial drugs such as hydroxychloroquine, azithromycin, various anti-viral medications, and recently, even host-directed therapies [2] [3] [4] [5] .", [["hydroxychloroquine", "CHEMICAL", 49, 67], ["azithromycin", "CHEMICAL", 69, 81], ["hydroxychloroquine", "CHEMICAL", 49, 67], ["azithromycin", "CHEMICAL", 69, 81], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 49, 67], ["azithromycin", "SIMPLE_CHEMICAL", 69, 81], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 158, 173], ["antimalarial drugs", "TREATMENT", 22, 40], ["hydroxychloroquine", "TREATMENT", 49, 67], ["azithromycin", "TREATMENT", 69, 81], ["various anti-viral medications", "TREATMENT", 83, 113]]], ["Although a majority of these drugs have been cited as potential candidates, their clinical efficacy and safety profile have not been completely evaluated.IntroductionChloroquine, an age old member of the WHO list of Essential medicines, has been studied extensively for its immunomodulatory properties and antiviral mechanisms [6] .", [["Chloroquine", "CHEMICAL", 166, 177], ["Chloroquine", "CHEMICAL", 166, 177], ["Chloroquine", "SIMPLE_CHEMICAL", 166, 177], ["these drugs", "TREATMENT", 23, 34], ["Chloroquine", "TREATMENT", 166, 177], ["Essential medicines", "TREATMENT", 216, 235], ["its immunomodulatory properties", "TREATMENT", 270, 301], ["antiviral mechanisms", "TREATMENT", 306, 326]]], ["Hydroxychloroquine is one such formulation which has come into light for its use in COVID-19 treatment given its proven efficacy in both laboratory and in vivo studies [7] .", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 84, 92], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 84, 92], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["COVID-19 treatment", "TREATMENT", 84, 102]]], ["It has been observed to inhibit ACE2 receptor-mediated entry of the SARS-CoV2 virus through various actions such as raising of intravesicular pH, inhibiting lysosomal activity, and affecting antigen processing [8] [9] [10] .", [["intravesicular", "ANATOMY", 127, 141], ["lysosomal", "ANATOMY", 157, 166], ["SARS", "DISEASE", 68, 72], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 32, 45], ["SARS-CoV2 virus", "ORGANISM", 68, 83], ["intravesicular", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 141], ["lysosomal", "CELLULAR_COMPONENT", 157, 166], ["ACE2 receptor", "PROTEIN", 32, 45], ["SARS-CoV2 virus", "SPECIES", 68, 83], ["ACE2 receptor", "TREATMENT", 32, 45], ["the SARS", "PROBLEM", 64, 72], ["CoV2 virus", "PROBLEM", 73, 83], ["intravesicular pH", "PROBLEM", 127, 144], ["inhibiting lysosomal activity", "PROBLEM", 146, 175], ["intravesicular pH", "OBSERVATION", 127, 144], ["lysosomal activity", "OBSERVATION", 157, 175]]], ["It has strong anti-inflammatory and immunomodulatory properties that are beneficial against the surge of cytokines that occur in the background of COVID-19 infection [7] [8] [9] [10] [11] .IntroductionThe reports of adverse effects, both minor and major, appear to be the limiting factor against the use of this drug [12] .", [["COVID-19", "CHEMICAL", 147, 155], ["infection", "DISEASE", 156, 165], ["COVID-19", "CHEMICAL", 147, 155], ["COVID-19", "SIMPLE_CHEMICAL", 147, 155], ["[7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 166, 187], ["cytokines", "PROTEIN", 105, 114], ["immunomodulatory properties", "TREATMENT", 36, 63], ["cytokines", "PROBLEM", 105, 114], ["COVID", "TEST", 147, 152], ["infection", "PROBLEM", 156, 165], ["adverse effects", "PROBLEM", 216, 231], ["this drug", "TREATMENT", 307, 316], ["strong", "OBSERVATION_MODIFIER", 7, 13], ["anti-inflammatory", "OBSERVATION_MODIFIER", 14, 31], ["immunomodulatory properties", "OBSERVATION_MODIFIER", 36, 63]]], ["Minor side effects range from nausea, vomiting, diarrhea, constipation, skin rash and itching, cutaneous hyperpigmentation, gastritis to name a few, while major side effects include retinal toxicity, maculopathies, acute pulmonary edema, reversible heart failure, and cardiac arrhythmias (QTc prolongation) [13] .", [["skin", "ANATOMY", 72, 76], ["cutaneous", "ANATOMY", 95, 104], ["retinal", "ANATOMY", 182, 189], ["pulmonary", "ANATOMY", 221, 230], ["heart", "ANATOMY", 249, 254], ["cardiac", "ANATOMY", 268, 275], ["nausea", "DISEASE", 30, 36], ["vomiting", "DISEASE", 38, 46], ["diarrhea", "DISEASE", 48, 56], ["constipation", "DISEASE", 58, 70], ["skin rash", "DISEASE", 72, 81], ["itching", "DISEASE", 86, 93], ["hyperpigmentation", "DISEASE", 105, 122], ["gastritis", "DISEASE", 124, 133], ["retinal toxicity", "DISEASE", 182, 198], ["maculopathies", "DISEASE", 200, 213], ["acute pulmonary edema", "DISEASE", 215, 236], ["heart failure", "DISEASE", 249, 262], ["cardiac arrhythmias", "DISEASE", 268, 287], ["skin", "ORGAN", 72, 76], ["retinal", "MULTI-TISSUE_STRUCTURE", 182, 189], ["pulmonary", "ORGAN", 221, 230], ["heart", "ORGAN", 249, 254], ["cardiac", "ORGAN", 268, 275], ["Minor side effects", "PROBLEM", 0, 18], ["nausea", "PROBLEM", 30, 36], ["vomiting", "PROBLEM", 38, 46], ["diarrhea", "PROBLEM", 48, 56], ["constipation", "PROBLEM", 58, 70], ["skin rash", "PROBLEM", 72, 81], ["itching", "PROBLEM", 86, 93], ["cutaneous hyperpigmentation", "PROBLEM", 95, 122], ["gastritis", "PROBLEM", 124, 133], ["retinal toxicity", "PROBLEM", 182, 198], ["maculopathies", "PROBLEM", 200, 213], ["acute pulmonary edema", "PROBLEM", 215, 236], ["reversible heart failure", "PROBLEM", 238, 262], ["cardiac arrhythmias", "PROBLEM", 268, 287], ["QTc prolongation)", "PROBLEM", 289, 306], ["side effects", "OBSERVATION_MODIFIER", 6, 18], ["constipation", "OBSERVATION", 58, 70], ["skin", "ANATOMY", 72, 76], ["rash", "OBSERVATION", 77, 81], ["itching", "OBSERVATION", 86, 93], ["cutaneous", "ANATOMY", 95, 104], ["hyperpigmentation", "OBSERVATION", 105, 122], ["gastritis", "OBSERVATION", 124, 133], ["retinal", "ANATOMY", 182, 189], ["toxicity", "OBSERVATION", 190, 198], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["pulmonary", "ANATOMY", 221, 230], ["edema", "OBSERVATION", 231, 236], ["reversible", "OBSERVATION_MODIFIER", 238, 248], ["heart", "ANATOMY", 249, 254], ["failure", "OBSERVATION", 255, 262], ["cardiac", "ANATOMY", 268, 275], ["arrhythmias", "OBSERVATION", 276, 287]]], ["Therefore, precautions needed while using these drugs include frequent monitoring of hematological parameters, serum electrolytes, blood sugar levels, renal and hepatic function tests, routine electrocardiography prior to initiation of the drug, and visual acuity testing.IntroductionSudden deaths reported in the West, following the administration of HCQ, are mainly due to the QT interval prolongation and torsades de pointes (TdP) in susceptible individuals [13] .", [["hematological", "ANATOMY", 85, 98], ["serum", "ANATOMY", 111, 116], ["blood", "ANATOMY", 131, 136], ["renal", "ANATOMY", 151, 156], ["hepatic", "ANATOMY", 161, 168], ["deaths", "DISEASE", 291, 297], ["HCQ", "CHEMICAL", 352, 355], ["QT interval prolongation", "DISEASE", 379, 403], ["torsades de pointes", "DISEASE", 408, 427], ["TdP", "DISEASE", 429, 432], ["sugar", "CHEMICAL", 137, 142], ["HCQ", "CHEMICAL", 352, 355], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["electrolytes", "SIMPLE_CHEMICAL", 117, 129], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["sugar", "SIMPLE_CHEMICAL", 137, 142], ["renal", "MULTI-TISSUE_STRUCTURE", 151, 156], ["hepatic", "MULTI-TISSUE_STRUCTURE", 161, 168], ["HCQ", "SIMPLE_CHEMICAL", 352, 355], ["precautions", "TREATMENT", 11, 22], ["these drugs", "TREATMENT", 42, 53], ["frequent monitoring", "TEST", 62, 81], ["hematological parameters", "TEST", 85, 109], ["serum electrolytes", "TEST", 111, 129], ["blood sugar levels", "TEST", 131, 149], ["renal and hepatic function tests", "TEST", 151, 183], ["routine electrocardiography", "TEST", 185, 212], ["the drug", "TREATMENT", 236, 244], ["visual acuity testing", "TEST", 250, 271], ["HCQ", "TREATMENT", 352, 355], ["the QT interval prolongation", "PROBLEM", 375, 403], ["torsades de pointes (TdP) in susceptible individuals", "PROBLEM", 408, 460], ["renal", "ANATOMY", 151, 156], ["hepatic", "ANATOMY", 161, 168]]], ["The risk of TdP is not a linear function of basal QTc or drug-induced prolongation in QTc interval.", [["TdP", "DISEASE", 12, 15], ["TdP", "PROBLEM", 12, 15], ["basal QTc", "PROBLEM", 44, 53], ["drug-induced prolongation in QTc interval", "PROBLEM", 57, 98], ["TdP", "OBSERVATION", 12, 15], ["basal QTc", "OBSERVATION", 44, 53]]], ["Moreover, not all patients with drug-induced QTc prolongation will develop TdP.", [["QTc prolongation", "DISEASE", 45, 61], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["drug-induced QTc prolongation", "PROBLEM", 32, 61]]], ["This side effect is rare, but co-prescription of other drugs such as azithromycin (which is also being recommended for the treatment of COVID-19) could amplify this risk [14, 15] .IntroductionAlthough there are sporadic case reports of sudden deaths, cardiomyopathy, and reversible heart failure, a large metaanalysis of HCQ use in rheumatoid arthritis, contrary to popular belief, pointed to reduced cardiovascular risk [16, 17] .IntroductionAcquired long QT syndrome (aLQTS), also known as drug-induced LQTS, has been studied to look for genetic variants associated with the condition.", [["heart", "ANATOMY", 282, 287], ["cardiovascular", "ANATOMY", 401, 415], ["azithromycin", "CHEMICAL", 69, 81], ["deaths", "DISEASE", 243, 249], ["cardiomyopathy", "DISEASE", 251, 265], ["heart failure", "DISEASE", 282, 295], ["HCQ", "CHEMICAL", 321, 324], ["rheumatoid arthritis", "DISEASE", 332, 352], ["long QT syndrome", "DISEASE", 452, 468], ["aLQTS", "DISEASE", 470, 475], ["LQTS", "DISEASE", 505, 509], ["azithromycin", "CHEMICAL", 69, 81], ["COVID-19", "CHEMICAL", 136, 144], ["HCQ", "CHEMICAL", 321, 324], ["azithromycin", "SIMPLE_CHEMICAL", 69, 81], ["heart", "ORGAN", 282, 287], ["HCQ", "SIMPLE_CHEMICAL", 321, 324], ["other drugs", "TREATMENT", 49, 60], ["azithromycin", "TREATMENT", 69, 81], ["COVID", "TEST", 136, 141], ["sudden deaths", "PROBLEM", 236, 249], ["cardiomyopathy", "PROBLEM", 251, 265], ["reversible heart failure", "PROBLEM", 271, 295], ["a large metaanalysis of HCQ", "PROBLEM", 297, 324], ["rheumatoid arthritis", "PROBLEM", 332, 352], ["reduced cardiovascular risk", "PROBLEM", 393, 420], ["Acquired long QT syndrome", "PROBLEM", 443, 468], ["genetic variants", "PROBLEM", 540, 556], ["cardiomyopathy", "OBSERVATION", 251, 265], ["reversible", "OBSERVATION_MODIFIER", 271, 281], ["heart", "ANATOMY", 282, 287], ["failure", "OBSERVATION", 288, 295], ["large", "OBSERVATION_MODIFIER", 299, 304], ["metaanalysis", "OBSERVATION", 305, 317], ["rheumatoid arthritis", "OBSERVATION", 332, 352]]], ["A number of studies have strongly supported the idea that variation, not only in KCNH2 (which codes for Potassium voltage gated channel) but also in other cardiac ion channels and associated genes, may predispose individuals to acquired LQTS [18, 19] .", [["cardiac ion", "ANATOMY", 155, 166], ["Potassium", "CHEMICAL", 104, 113], ["LQTS", "DISEASE", 237, 241], ["Potassium", "CHEMICAL", 104, 113], ["KCNH2", "GENE_OR_GENE_PRODUCT", 81, 86], ["KCNH2", "PROTEIN", 81, 86], ["Potassium voltage gated channel", "PROTEIN", 104, 135], ["cardiac ion channels", "PROTEIN", 155, 175], ["Potassium voltage gated channel", "TREATMENT", 104, 135], ["cardiac", "ANATOMY", 155, 162], ["ion channels", "OBSERVATION", 163, 175]]], ["However, a lot of this data has been generated from Western literature.IntroductionFirstly, data regarding response and reaction of Indians to HCQ is lacking despite its widespread use in malaria, autoimmune disorders, inflammatory conditions, dermatological complaints, and even type 2 diabetes mellitus.", [["HCQ", "CHEMICAL", 143, 146], ["malaria", "DISEASE", 188, 195], ["autoimmune disorders", "DISEASE", 197, 217], ["dermatological complaints", "DISEASE", 244, 269], ["type 2 diabetes mellitus", "DISEASE", 280, 304], ["HCQ", "CHEMICAL", 143, 146], ["HCQ", "SIMPLE_CHEMICAL", 143, 146], ["HCQ", "TREATMENT", 143, 146], ["malaria", "PROBLEM", 188, 195], ["autoimmune disorders", "PROBLEM", 197, 217], ["inflammatory conditions", "PROBLEM", 219, 242], ["dermatological complaints", "PROBLEM", 244, 269], ["type 2 diabetes mellitus", "PROBLEM", 280, 304], ["malaria", "OBSERVATION", 188, 195], ["inflammatory", "OBSERVATION_MODIFIER", 219, 231], ["diabetes mellitus", "OBSERVATION", 287, 304]]], ["Secondly, mutations and variants in the channels in an Indian community based-sample will help bridge the gap between genetic factors, influence of the race thereby and other possible drug interaction and reactions.Advisory for HCQ Prophylaxis in HR Population as Declared by ICMRThe measures to contain the spread of COVID-19 such as social distancing, hand hygiene, surveillance, and isolation of persons suspected or confirmed to have infection have been considered as mainstay.", [["hand", "ANATOMY", 354, 358], ["HCQ", "CHEMICAL", 228, 231], ["infection", "DISEASE", 438, 447], ["HCQ", "CHEMICAL", 228, 231], ["HCQ", "SIMPLE_CHEMICAL", 228, 231], ["hand", "ORGANISM_SUBDIVISION", 354, 358], ["persons", "ORGANISM", 399, 406], ["persons", "SPECIES", 399, 406], ["mutations and variants", "PROBLEM", 10, 32], ["HCQ Prophylaxis", "TREATMENT", 228, 243], ["COVID", "TEST", 318, 323], ["infection", "PROBLEM", 438, 447], ["infection", "OBSERVATION", 438, 447]]], ["Government authorities have issued guidelines to healthcare workers and public, advising strict adherence to above measures and acknowledge the limited role of drugs in the treatment and prophylaxis.Advisory for HCQ Prophylaxis in HR Population as Declared by ICMRThe use of HCQ and its efficacy in the treatment against SARS-CoV2arebasedonlaboratorystudies,pre-clinicaldata and risk-benefit considerations.", [["HCQ", "CHEMICAL", 212, 215], ["HCQ", "CHEMICAL", 275, 278], ["SARS", "DISEASE", 321, 325], ["HCQ", "CHEMICAL", 212, 215], ["HCQ", "CHEMICAL", 275, 278], ["HCQ", "SIMPLE_CHEMICAL", 212, 215], ["HCQ", "SIMPLE_CHEMICAL", 275, 278], ["above measures", "TREATMENT", 109, 123], ["drugs", "TREATMENT", 160, 165], ["the treatment", "TREATMENT", 169, 182], ["prophylaxis", "TREATMENT", 187, 198], ["HCQ Prophylaxis", "TREATMENT", 212, 227], ["HCQ", "TREATMENT", 275, 278], ["the treatment", "TREATMENT", 299, 312], ["SARS", "PROBLEM", 321, 325], ["CoV2arebasedonlaboratorystudies", "TREATMENT", 326, 357], ["pre-clinicaldata", "TREATMENT", 358, 374]]], ["The Indian National Taskforce for COVID-19 recommends the use of HCQ for prophylaxis of SARS-CoV2 infection for \"all asymptomatic healthcare workers (containment and treatment), asymptomatic healthcare workers (non-COVID hospitals/non-COVID areas of COVID hospitals/blocks), and the asymptomatic frontlineworkers(surveillanceworkers-containmentzones and paramilitary/police personnel involved in COVID-19related activities)-400 mg twice a day on day 1, 400 mg once weekly for the next 7 weeks, taken with meals and asymptomatic household contacts of laboratory confirmed cases-400 mg twice a day on day 1, followed by 400 mg once weekly forthenext3weekstakenwithmeals\" [20] .However,thedrugis contraindicated for prophylaxis in children under 15 years of age, known cases of retinopathy, hypersensitivity to the drug and other 4-aminoquinoline compounds, G6PD deficiency, and any preexisting cardiomyopathy and cardiac rhythm disorders.", [["cardiac", "ANATOMY", 911, 918], ["HCQ", "CHEMICAL", 65, 68], ["SARS-CoV2 infection", "DISEASE", 88, 107], ["thedrugis", "CHEMICAL", 683, 692], ["retinopathy", "DISEASE", 775, 786], ["hypersensitivity", "DISEASE", 788, 804], ["4-aminoquinoline", "CHEMICAL", 827, 843], ["G6PD deficiency", "DISEASE", 855, 870], ["cardiomyopathy", "DISEASE", 892, 906], ["cardiac rhythm disorders", "DISEASE", 911, 935], ["HCQ", "CHEMICAL", 65, 68], ["4-aminoquinoline", "CHEMICAL", 827, 843], ["HCQ", "SIMPLE_CHEMICAL", 65, 68], ["thedrugis", "SIMPLE_CHEMICAL", 683, 692], ["children", "ORGANISM", 728, 736], ["4-aminoquinoline compounds", "SIMPLE_CHEMICAL", 827, 853], ["G6PD", "GENE_OR_GENE_PRODUCT", 855, 859], ["cardiac", "ORGAN", 911, 918], ["G6PD", "PROTEIN", 855, 859], ["children", "SPECIES", 728, 736], ["COVID", "TREATMENT", 34, 39], ["HCQ", "TREATMENT", 65, 68], ["prophylaxis", "TREATMENT", 73, 84], ["SARS", "PROBLEM", 88, 92], ["CoV2 infection", "PROBLEM", 93, 107], ["treatment", "TREATMENT", 166, 175], ["COVID-19related activities)", "TREATMENT", 396, 423], ["prophylaxis", "TREATMENT", 713, 724], ["retinopathy", "PROBLEM", 775, 786], ["hypersensitivity", "PROBLEM", 788, 804], ["the drug", "TREATMENT", 808, 816], ["other 4-aminoquinoline compounds", "PROBLEM", 821, 853], ["G6PD deficiency", "PROBLEM", 855, 870], ["any preexisting cardiomyopathy", "PROBLEM", 876, 906], ["cardiac rhythm disorders", "PROBLEM", 911, 935], ["retinopathy", "OBSERVATION", 775, 786], ["G6PD deficiency", "OBSERVATION", 855, 870], ["cardiomyopathy", "OBSERVATION", 892, 906], ["cardiac", "ANATOMY", 911, 918], ["rhythm disorders", "OBSERVATION", 919, 935]]], ["With available evidence for its safety and beneficial effect as a prophylactic drug against SARS-COV-2 during the earlier recommended 8-week period, the experts further recommended for its use beyond 8 weeks on weekly dosage with strictmonitoringofclinicalandECGparameterswhichwould alsoensurethatthetherapyisgivenundersupervision.MethodsA PubMed Database search was conducted.", [["SARS", "DISEASE", 92, 96], ["a prophylactic drug", "TREATMENT", 64, 83], ["SARS", "PROBLEM", 92, 96], ["strictmonitoringofclinicalandECGparameterswhichwould alsoensurethatthetherapyisgivenundersupervision", "TREATMENT", 230, 330], ["MethodsA", "TREATMENT", 331, 339]]], ["The search strate g y w a s c a r r i e d o u t u s i n g k e y w o r d s s u c h a s \"Hydroxychloroquine,\" \"Chloroquine,\" \"Cardiac side effects,\" and \"India.\"", [["Cardiac", "ANATOMY", 124, 131], ["Hydroxychloroquine", "CHEMICAL", 87, 105], ["Chloroquine", "CHEMICAL", 109, 120], ["Hydroxychloroquine", "CHEMICAL", 87, 105], ["Chloroquine", "CHEMICAL", 109, 120], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 87, 105], ["Chloroquine", "SIMPLE_CHEMICAL", 109, 120], ["u s", "TEST", 48, 51], ["Hydroxychloroquine", "TREATMENT", 87, 105], ["Chloroquine", "TREATMENT", 109, 120], ["Cardiac side effects", "PROBLEM", 124, 144]]], ["O u r s e a r c h s t r a t e g y w a s ( ( ( C h l o r o q u i n e O R Hydroxychloroquine)) AND (Deaths OR Fatal outcome OR, Cardiac OR heart OR side-effects OR side-effect OR side effects OR adverse event OR adverse reaction OR arrhythmia OR block OR QT prolongation OR QTc Prolongation)) AND India).MethodsWe included clinical trials, research studies, case reports, and randomized control trials that employed the use of HCQ/ CQ at any point in the treatment of patients of Indian origin.", [["heart", "ANATOMY", 137, 142], ["arrhythmia", "DISEASE", 230, 240], ["HCQ", "CHEMICAL", 425, 428], ["CQ", "CHEMICAL", 430, 432], ["Hydroxychloroquine", "CHEMICAL", 72, 90], ["HCQ", "CHEMICAL", 425, 428], ["heart", "ORGAN", 137, 142], ["HCQ", "SIMPLE_CHEMICAL", 425, 428], ["CQ", "SIMPLE_CHEMICAL", 430, 432], ["patients", "ORGANISM", 466, 474], ["patients", "SPECIES", 466, 474], ["a s", "TEST", 36, 39], ["C", "TEST", 46, 47], ["u i", "TEST", 60, 63], ["Hydroxychloroquine", "TREATMENT", 72, 90], ["Cardiac", "TEST", 126, 133], ["side effects", "PROBLEM", 177, 189], ["adverse event", "PROBLEM", 193, 206], ["adverse reaction", "PROBLEM", 210, 226], ["arrhythmia", "PROBLEM", 230, 240], ["block", "PROBLEM", 244, 249], ["QT prolongation", "PROBLEM", 253, 268], ["QTc Prolongation", "TREATMENT", 272, 288], ["research studies", "TEST", 338, 354], ["randomized control trials", "TREATMENT", 374, 399], ["HCQ/ CQ", "TREATMENT", 425, 432], ["Cardiac", "ANATOMY", 126, 133], ["heart", "ANATOMY", 137, 142]]], ["Title screening, followed by relevant abstract, filtering, and finally, a full-text screening was done as per inclusion and exclusion criteria.Inclusion Criteria-Patients: Indian patients both adult and pediatric populationData Extraction (Selection and Coding)Three reviewers independently screened titles and abstract of relevant search results that met the inclusion criteria prior to screening full-text papers.", [["Patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 179, 187], ["Patients", "SPECIES", 162, 170], ["patients", "SPECIES", 179, 187], ["Title screening", "TEST", 0, 15], ["a full-text screening", "TEST", 72, 93]]], ["Details that were extracted to included author and journal details, year of publication, sample s i z e , a g e , s e x , i n d i c a t i o n f o r r a t i o n a l u s e o f hydroxychloroquine, duration for treatment, the number of patients that reported various minor side effects, the number of patients that reported major side effects, and deaths, if any, during the period of the study.", [["hydroxychloroquine", "CHEMICAL", 174, 192], ["deaths", "DISEASE", 344, 350], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 174, 192], ["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 297, 305], ["hydroxychloroquine", "TREATMENT", 174, 192], ["treatment", "TREATMENT", 207, 216], ["the study", "TEST", 381, 390]]], ["Our focus, however, was on side effects observed in the Indian population with HCQ use.", [["HCQ", "CHEMICAL", 79, 82], ["HCQ", "CHEMICAL", 79, 82], ["HCQ", "SIMPLE_CHEMICAL", 79, 82], ["HCQ use", "TREATMENT", 79, 86]]], ["Once this data was retrieved, we calculated the total number of subjects across all reports that received HCQ and the proportion which developed both minor and serious adverse reactions.Statistical AnalysisThe data were extracted in Google Sheets and Excel in numbers and converted later to percentages.ResultsWith our aforementioned search strategy and a couple of other similar searches that were tried, we screened a total of 317 articles (Fig. 1 ).", [["HCQ", "CHEMICAL", 106, 109], ["HCQ", "CHEMICAL", 106, 109], ["HCQ", "SIMPLE_CHEMICAL", 106, 109], ["HCQ", "TREATMENT", 106, 109], ["serious adverse reactions", "PROBLEM", 160, 185], ["Statistical Analysis", "TEST", 186, 206]]], ["A total of 3123 Indian patients were treated with either HCQ or CQ for different indications and at different doses, for different durations.ResultsWe recorded a total 253 adverse reactions that were reported in these articles.", [["HCQ", "CHEMICAL", 57, 60], ["CQ", "CHEMICAL", 64, 66], ["HCQ", "CHEMICAL", 57, 60], ["patients", "ORGANISM", 23, 31], ["HCQ", "SIMPLE_CHEMICAL", 57, 60], ["CQ", "SIMPLE_CHEMICAL", 64, 66], ["patients", "SPECIES", 23, 31], ["HCQ", "TREATMENT", 57, 60], ["CQ", "TREATMENT", 64, 66], ["different indications", "TREATMENT", 71, 92], ["a total 253 adverse reactions", "PROBLEM", 160, 189]]], ["Adverse reactions were further grouped as non-cardiac and cardiac.", [["non-cardiac", "ANATOMY", 42, 53], ["cardiac", "ANATOMY", 58, 65], ["cardiac", "ORGAN", 58, 65], ["Adverse reactions", "PROBLEM", 0, 17], ["cardiac", "ANATOMY", 58, 65]]], ["Non-cardiac reactions were 232 (Fig. 2 ) in all and included minor reversible ones such as urticaria, itching, epigastric pain, nausea, diarrhea, constipation, and also some that were potentially life-threatening, such as psychosis, mania, retinal toxicity, hypoglycemia, methem o g l o b i n e m i a , e x t r a p y r a m i d a l s y n d r o m e s , a n d Parkinsonism, to name a few.", [["Non-cardiac", "ANATOMY", 0, 11], ["epigastric", "ANATOMY", 111, 121], ["retinal", "ANATOMY", 240, 247], ["urticaria", "DISEASE", 91, 100], ["itching", "DISEASE", 102, 109], ["epigastric pain", "DISEASE", 111, 126], ["nausea", "DISEASE", 128, 134], ["diarrhea", "DISEASE", 136, 144], ["constipation", "DISEASE", 146, 158], ["psychosis", "DISEASE", 222, 231], ["mania", "DISEASE", 233, 238], ["retinal toxicity", "DISEASE", 240, 256], ["hypoglycemia", "DISEASE", 258, 270], ["Parkinsonism", "DISEASE", 357, 369], ["epigastric", "ORGANISM_SUBDIVISION", 111, 121], ["retinal", "MULTI-TISSUE_STRUCTURE", 240, 247], ["Non-cardiac reactions", "PROBLEM", 0, 21], ["minor reversible ones", "PROBLEM", 61, 82], ["urticaria", "PROBLEM", 91, 100], ["itching", "PROBLEM", 102, 109], ["epigastric pain", "PROBLEM", 111, 126], ["nausea", "PROBLEM", 128, 134], ["diarrhea", "PROBLEM", 136, 144], ["constipation", "PROBLEM", 146, 158], ["psychosis", "PROBLEM", 222, 231], ["mania", "PROBLEM", 233, 238], ["retinal toxicity", "PROBLEM", 240, 256], ["hypoglycemia", "PROBLEM", 258, 270], ["e s", "TEST", 345, 348], ["Parkinsonism", "PROBLEM", 357, 369], ["minor reversible", "OBSERVATION_MODIFIER", 61, 77], ["urticaria", "OBSERVATION", 91, 100], ["epigastric", "ANATOMY", 111, 121], ["pain", "OBSERVATION", 122, 126], ["constipation", "OBSERVATION", 146, 158], ["retinal", "ANATOMY", 240, 247]]], ["Cardiac-related adverse effects (Fig. 3) were 19 in all, 13 QTc prolongations, 2 chest pains, 1 cardiovascular collapse, 1 recurrent syncopal attack, 1 acute pulmonary edema, and 1 cardiomyopathy.", [["Cardiac", "ANATOMY", 0, 7], ["chest", "ANATOMY", 81, 86], ["cardiovascular", "ANATOMY", 96, 110], ["pulmonary", "ANATOMY", 158, 167], ["QTc prolongations", "DISEASE", 60, 77], ["chest pains", "DISEASE", 81, 92], ["cardiovascular collapse", "DISEASE", 96, 119], ["syncopal", "DISEASE", 133, 141], ["acute pulmonary edema", "DISEASE", 152, 173], ["cardiomyopathy", "DISEASE", 181, 195], ["Cardiac", "ORGAN", 0, 7], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 158, 173], ["adverse effects", "PROBLEM", 16, 31], ["13 QTc prolongations", "PROBLEM", 57, 77], ["2 chest pains", "PROBLEM", 79, 92], ["1 cardiovascular collapse", "PROBLEM", 94, 119], ["1 recurrent syncopal attack", "PROBLEM", 121, 148], ["1 acute pulmonary edema", "PROBLEM", 150, 173], ["1 cardiomyopathy", "PROBLEM", 179, 195], ["chest", "ANATOMY", 81, 86], ["cardiovascular", "ANATOMY", 96, 110], ["collapse", "OBSERVATION", 111, 119], ["recurrent", "OBSERVATION_MODIFIER", 123, 132], ["syncopal attack", "OBSERVATION", 133, 148], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["pulmonary", "ANATOMY", 158, 167], ["edema", "OBSERVATION", 168, 173], ["cardiomyopathy", "OBSERVATION", 181, 195]]], ["Two deaths were reported whose causes were not mentioned or known (Table 1 ).DiscussionHydroxychloroquine came as a beacon of hope in the battle against the COVID-19 pandemic.", [["deaths", "DISEASE", 4, 10], ["Hydroxychloroquine", "CHEMICAL", 87, 105], ["Hydroxychloroquine", "CHEMICAL", 87, 105], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 87, 105], ["Hydroxychloroquine", "TREATMENT", 87, 105]]], ["Given its dubious safety profile, there are two schools of thought about using HCQ for chemoprophylaxis.", [["HCQ", "CHEMICAL", 79, 82], ["HCQ", "CHEMICAL", 79, 82], ["HCQ", "SIMPLE_CHEMICAL", 79, 82], ["HCQ", "TREATMENT", 79, 82], ["chemoprophylaxis", "TREATMENT", 87, 103]]], ["However, we believe that there might be more to the story than that meets the eye.", [["eye", "ANATOMY", 78, 81], ["eye", "ORGAN", 78, 81], ["eye", "ANATOMY", 78, 81]]], ["It might not be prudent to replicate the number of adverse reactions observed in Western population and superimpose them on the Indian patient.DiscussionThe Indian portal for reporting adverse events, also known as PvPI (Pharmaco-vigilance Programme of India) under the Indian Pharmacopeia Commission, Ghaziabad, was checked prior to the start of the search across PubMed for details regarding the ADRs developing from administration of CQ/ HCQ.", [["PvPI", "CHEMICAL", 215, 219], ["ADRs", "DISEASE", 398, 402], ["CQ", "CHEMICAL", 437, 439], ["HCQ", "CHEMICAL", 441, 444], ["HCQ", "CHEMICAL", 441, 444], ["patient", "ORGANISM", 135, 142], ["CQ", "SIMPLE_CHEMICAL", 437, 439], ["HCQ", "SIMPLE_CHEMICAL", 441, 444], ["patient", "SPECIES", 135, 142], ["adverse reactions", "PROBLEM", 51, 68], ["adverse events", "PROBLEM", 185, 199], ["the ADRs", "PROBLEM", 394, 402], ["CQ/ HCQ", "TREATMENT", 437, 444], ["portal", "ANATOMY", 164, 170]]], ["However, we could not get any information available in the open public database.DiscussionWe also searched Vigiaccess [13] , the online database for ICSRs (Individual case Safety Reports) for information regarding geographic distribution of ADRs.", [["ADRs", "DISEASE", 241, 245], ["ADRs", "PROBLEM", 241, 245]]], ["However, it only gave data in broad headings of Africa, the Americas, Asia, Europe, and Oceania, thereby limiting our data collection.", [["Africa", "PROBLEM", 48, 54]]], ["It was interesting to note that Americas noted 56% of the ADRs from use of hydroxychloroquine, Europe 27%, and Asia 14%.", [["ADRs", "DISEASE", 58, 62], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["the ADRs", "PROBLEM", 54, 62], ["hydroxychloroquine", "TREATMENT", 75, 93], ["Europe", "TREATMENT", 95, 101]]], ["However, it should be borne in mind that underreporting could also be an attributing factor to this.DiscussionThe latest revised advisory released by Indian Council of Medical Research (ICMR) states that HCQ prophylaxis among 1323 HCWs indicated mild adverse effects such as nausea (8.9%), abdominal pain (7.3%), vomiting (1.5%), hypoglycemia (1.7%), and cardiovascular effects (1.9%).", [["abdominal", "ANATOMY", 290, 299], ["cardiovascular", "ANATOMY", 355, 369], ["HCQ", "CHEMICAL", 204, 207], ["nausea", "DISEASE", 275, 281], ["abdominal pain", "DISEASE", 290, 304], ["vomiting", "DISEASE", 313, 321], ["hypoglycemia", "DISEASE", 330, 342], ["HCQ", "CHEMICAL", 204, 207], ["HCQ", "SIMPLE_CHEMICAL", 204, 207], ["abdominal", "ORGANISM_SUBDIVISION", 290, 299], ["HCQ prophylaxis", "TREATMENT", 204, 219], ["mild adverse effects", "PROBLEM", 246, 266], ["nausea", "PROBLEM", 275, 281], ["abdominal pain", "PROBLEM", 290, 304], ["vomiting", "PROBLEM", 313, 321], ["hypoglycemia", "PROBLEM", 330, 342], ["cardiovascular effects", "PROBLEM", 355, 377], ["mild", "OBSERVATION_MODIFIER", 246, 250], ["abdominal", "ANATOMY", 290, 299], ["cardiovascular", "ANATOMY", 355, 369]]], ["However, as per the data from the PvPI, there have been 214 reported instances of adverse drug reactions associated with prophylactic HCQ use.", [["adverse drug reactions", "DISEASE", 82, 104], ["HCQ", "CHEMICAL", 134, 137], ["HCQ", "CHEMICAL", 134, 137], ["HCQ", "SIMPLE_CHEMICAL", 134, 137], ["adverse drug reactions", "PROBLEM", 82, 104], ["prophylactic HCQ use", "TREATMENT", 121, 141]]], ["Of these, 7 were serious individual case safety reports with prolongation of the QT interval on ECG in 3 cases.", [["the QT interval", "PROBLEM", 77, 92], ["ECG", "TEST", 96, 99]]], ["Then again, the denominator for this value, that is, the overall number of healthcare workers who took prophylactic HCQ, is not available.", [["HCQ", "CHEMICAL", 116, 119], ["HCQ", "CHEMICAL", 116, 119], ["HCQ", "SIMPLE_CHEMICAL", 116, 119], ["prophylactic HCQ", "TREATMENT", 103, 119]]], ["Details regarding any underlying contraindications were also not mentioned.DiscussionIncluding the ICMR data, 1.9% of the 1323 HCWs who took HCQ as prophylaxis developed cardiovascular risks (n = 25).", [["cardiovascular", "ANATOMY", 170, 184], ["HCQ", "CHEMICAL", 141, 144], ["cardiovascular risks", "DISEASE", 170, 190], ["HCQ", "CHEMICAL", 141, 144], ["HCQ", "SIMPLE_CHEMICAL", 141, 144], ["any underlying contraindications", "PROBLEM", 18, 50], ["the ICMR data", "TEST", 95, 108], ["HCQ", "TREATMENT", 141, 144], ["prophylaxis", "TREATMENT", 148, 159], ["cardiovascular risks", "PROBLEM", 170, 190]]], ["Summing up both these samples (1323 + 3123), we get a total sample size of 4446 individuals who have been subjected to HCQ, both in therapeutic and prophylactic doses.", [["samples", "ANATOMY", 22, 29], ["HCQ", "CHEMICAL", 119, 122], ["HCQ", "CHEMICAL", 119, 122], ["HCQ", "SIMPLE_CHEMICAL", 119, 122], ["HCQ", "TREATMENT", 119, 122], ["prophylactic doses", "TREATMENT", 148, 166]]], ["About 0.98% is at risk of developing cardiovascular side effects according to this number.DiscussionBased on the evidence released by ICMR and PvPI, they have opined that HCQ is relatively safe, when certain contraindications are avoided, and that it has considerable benefit as a prophylactic option.", [["cardiovascular", "ANATOMY", 37, 51], ["HCQ", "CHEMICAL", 171, 174], ["HCQ", "CHEMICAL", 171, 174], ["cardiovascular", "ANATOMICAL_SYSTEM", 37, 51], ["PvPI", "SIMPLE_CHEMICAL", 143, 147], ["HCQ", "SIMPLE_CHEMICAL", 171, 174], ["developing cardiovascular side effects", "PROBLEM", 26, 64], ["PvPI", "TREATMENT", 143, 147], ["a prophylactic option", "TREATMENT", 279, 300], ["cardiovascular", "OBSERVATION", 37, 51]]], ["The advisory recommends HCQ administration under strict medical supervision and informed consent.DiscussionLimitations faced during data collection included the following:Discussion& A number of adverse events were mentioned, but details of the same were not provided in the studies.", [["HCQ", "CHEMICAL", 24, 27], ["HCQ", "CHEMICAL", 24, 27], ["HCQ", "SIMPLE_CHEMICAL", 24, 27], ["HCQ administration", "TREATMENT", 24, 42], ["the studies", "TEST", 271, 282]]], ["So, data regarding types of minor reactions could not be extractedDiscussionRecords screened using relevant search strategy n= 317DiscussionRecords identified through database screening n=1885DiscussionRecords included in quantitative and qualitative analysis n=105DiscussionAbstract and full text assessed for eligibility n=106DiscussionRecords excluded n=212DiscussionFull text articles excluded with reasons n=1 Fig. 1 Fig. 3 Frequency of various cardiac side effects following HCQ use from these papers.", [["cardiac", "ANATOMY", 450, 457], ["HCQ", "CHEMICAL", 481, 484], ["HCQ", "CHEMICAL", 481, 484], ["cardiac", "ORGAN", 450, 457], ["HCQ", "SIMPLE_CHEMICAL", 481, 484], ["minor reactions", "PROBLEM", 28, 43], ["various cardiac side effects", "PROBLEM", 442, 470]]], ["Many papers quoted these reactions as self-limiting and deemed it unimportant to report. & Multi-centric and multi-ethnic cohorts that were used for RCTs did not mention the race of the individual whose ADR was recorded.", [["ADR", "CHEMICAL", 203, 206], ["these reactions", "PROBLEM", 19, 34], ["Multi-centric and multi-ethnic cohorts", "TREATMENT", 91, 129], ["RCTs", "TREATMENT", 149, 153]]], ["We have, however, included the number of events mentioned because we believed it was better to err on the higher side (for example, this was true for one of the deaths that were reported by a multi-centric study conducted across Asia, Table 1 ). & Similarly, the case report that mentioned recurrent syncopal attacks as a drug reaction lacks the proof for the same.", [["deaths", "DISEASE", 161, 167], ["syncopal", "DISEASE", 300, 308], ["a multi-centric study", "TEST", 190, 211], ["recurrent syncopal attacks", "PROBLEM", 290, 316], ["a drug reaction", "PROBLEM", 320, 335]]], ["It was hypothesized that it could be from the disease process (rheumatoid arthritis-nodule in the heart tissue, in this case) or from cardiotoxicity due to the drug.", [["nodule", "ANATOMY", 84, 90], ["heart tissue", "ANATOMY", 98, 110], ["rheumatoid arthritis", "DISEASE", 63, 83], ["cardiotoxicity", "DISEASE", 134, 148], ["heart tissue", "TISSUE", 98, 110], ["the disease process", "PROBLEM", 42, 61], ["rheumatoid arthritis", "PROBLEM", 63, 83], ["nodule in the heart tissue", "PROBLEM", 84, 110], ["cardiotoxicity", "PROBLEM", 134, 148], ["disease", "OBSERVATION", 46, 53], ["rheumatoid", "OBSERVATION_MODIFIER", 63, 73], ["arthritis", "OBSERVATION", 74, 83], ["nodule", "OBSERVATION", 84, 90], ["heart", "ANATOMY", 98, 103], ["tissue", "ANATOMY_MODIFIER", 104, 110]]], ["We, however, included the event in the study, in an attempt to be more inclusive of possible adverse reactions (Table 1 ) & We also found an article that reported ADRs of many different drugs in a tertiary care during a specified period of time, but we could not use this article due to lack of information on the denominator, that is, the total number of patients receiving the drug in the study setup. & Lastly, an important data that was elusive in these studies was details pertaining to demographic variables, comorbidities, any underlying structural heart diseases, history of co-administration with other QT interval prolonging medications such as macrolides, quinolones, antihistaminics, antiviral, antiarrhythmic, or antifungal drugs. & Apart from these limitations, it is important to note that chloroquine is more widely available in the Indian context given its continued use against malaria, while HCQ is more often prescribed for inflammatory conditions.", [["heart", "ANATOMY", 556, 561], ["ADRs", "DISEASE", 163, 167], ["heart diseases", "DISEASE", 556, 570], ["macrolides", "CHEMICAL", 655, 665], ["quinolones", "CHEMICAL", 667, 677], ["antihistaminics", "CHEMICAL", 679, 694], ["chloroquine", "CHEMICAL", 805, 816], ["malaria", "DISEASE", 896, 903], ["HCQ", "CHEMICAL", 911, 914], ["macrolides", "CHEMICAL", 655, 665], ["quinolones", "CHEMICAL", 667, 677], ["chloroquine", "CHEMICAL", 805, 816], ["HCQ", "CHEMICAL", 911, 914], ["patients", "ORGANISM", 356, 364], ["heart", "ORGAN", 556, 561], ["quinolones", "SIMPLE_CHEMICAL", 667, 677], ["antihistaminics", "SIMPLE_CHEMICAL", 679, 694], ["chloroquine", "SIMPLE_CHEMICAL", 805, 816], ["HCQ", "SIMPLE_CHEMICAL", 911, 914], ["patients", "SPECIES", 356, 364], ["the study", "TEST", 35, 44], ["adverse reactions", "PROBLEM", 93, 110], ["a tertiary care", "TREATMENT", 195, 210], ["the drug", "TREATMENT", 375, 383], ["these studies", "TEST", 452, 465], ["comorbidities", "PROBLEM", 515, 528], ["any underlying structural heart diseases", "PROBLEM", 530, 570], ["co-administration", "TREATMENT", 583, 600], ["other QT interval prolonging medications", "TREATMENT", 606, 646], ["macrolides", "TREATMENT", 655, 665], ["quinolones", "TREATMENT", 667, 677], ["antihistaminics", "TREATMENT", 679, 694], ["antiviral", "TREATMENT", 696, 705], ["antiarrhythmic", "TREATMENT", 707, 721], ["antifungal drugs", "TREATMENT", 726, 742], ["chloroquine", "TREATMENT", 805, 816], ["malaria", "PROBLEM", 896, 903], ["HCQ", "TREATMENT", 911, 914], ["inflammatory conditions", "PROBLEM", 944, 967], ["heart", "ANATOMY", 556, 561], ["diseases", "OBSERVATION", 562, 570]]], ["Therefore, this further impedes our data collection with reference to HCQ adverse effects.ConclusionWhile several intervention trials are currently underway with HCQ in COVID-19 patients at different doses in the international level, we believe it would be wise to conduct similar large-scale trials on both COVID-19 patients and others taking HCQ for multiple other indications among the Indian patient subgroup.", [["HCQ", "CHEMICAL", 70, 73], ["HCQ", "CHEMICAL", 162, 165], ["HCQ", "CHEMICAL", 344, 347], ["HCQ", "CHEMICAL", 70, 73], ["HCQ", "CHEMICAL", 162, 165], ["HCQ", "CHEMICAL", 344, 347], ["HCQ", "SIMPLE_CHEMICAL", 70, 73], ["HCQ", "SIMPLE_CHEMICAL", 162, 165], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 317, 325], ["HCQ", "SIMPLE_CHEMICAL", 344, 347], ["patient", "ORGANISM", 396, 403], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 317, 325], ["patient", "SPECIES", 396, 403], ["our data collection", "TEST", 32, 51], ["HCQ adverse effects", "PROBLEM", 70, 89], ["several intervention trials", "TREATMENT", 106, 133], ["HCQ in COVID", "TREATMENT", 162, 174], ["similar large-scale trials", "TREATMENT", 273, 299], ["HCQ", "TREATMENT", 344, 347]]], ["Also, a pharmacogenomic study to understand the interplay of HCQ and genetic factors will throw light on Indians and their propensity to develop cardiac morbidities and other potentially life-threatening side effects following the administration of HCQ.ConclusionIn the possibility that race might prove to be protective against the ill-effects of HCQ, it will help in allaying the fear among the public and putting to rest any panic regarding the use of the drug in prophylaxis against COVID-19.", [["cardiac", "ANATOMY", 145, 152], ["HCQ", "CHEMICAL", 61, 64], ["cardiac morbidities", "DISEASE", 145, 164], ["HCQ", "CHEMICAL", 249, 252], ["HCQ", "CHEMICAL", 348, 351], ["panic", "DISEASE", 428, 433], ["HCQ", "CHEMICAL", 61, 64], ["HCQ", "CHEMICAL", 249, 252], ["HCQ", "CHEMICAL", 348, 351], ["HCQ", "SIMPLE_CHEMICAL", 61, 64], ["cardiac", "ORGAN", 145, 152], ["HCQ", "SIMPLE_CHEMICAL", 249, 252], ["HCQ", "SIMPLE_CHEMICAL", 348, 351], ["a pharmacogenomic study", "TEST", 6, 29], ["HCQ", "TREATMENT", 61, 64], ["cardiac morbidities", "PROBLEM", 145, 164], ["HCQ", "TREATMENT", 249, 252], ["HCQ", "TREATMENT", 348, 351], ["any panic", "PROBLEM", 424, 433], ["the drug in prophylaxis", "TREATMENT", 455, 478], ["COVID", "TEST", 487, 492]]], ["However, in the absence of the same, physicians must be urged to be more cautious and watchful during the period of drug administration and carry out the required monitoring.Compliance with Ethical StandardsConflict of Interest The authors declare that they have no conflict of interest.Compliance with Ethical StandardsEthical Approval This article does not contain any studies with human participants or animals performed by any of the authors.Compliance with Ethical StandardsInformed Consent Not applicable.", [["human", "ORGANISM", 384, 389], ["human", "SPECIES", 384, 389], ["participants", "SPECIES", 390, 402], ["human", "SPECIES", 384, 389], ["drug administration", "TREATMENT", 116, 135], ["Ethical Standards", "TREATMENT", 190, 207], ["Ethical StandardsEthical Approval", "TREATMENT", 303, 336]]], ["This article does not contain any studies with human participants or animals performed by any of the authors.", [["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["participants", "SPECIES", 53, 65], ["human", "SPECIES", 47, 52]]]], "f1be0614a0ef5bea9232a54c05d324d5edba8033": [["INTRODUCTIONIn spite of the global threat of emerging and re-emerging infectious diseases and concerns about international terrorism, travel remains one of the largest 'businesses' in the world.", [["infectious diseases", "DISEASE", 70, 89], ["re-emerging infectious diseases", "PROBLEM", 58, 89], ["infectious", "OBSERVATION", 70, 80]]], ["Over the last decade, the number of travelers crossing international borders has grown from 457 million in 1990 to 763 million in 2004.", [["number", "OBSERVATION_MODIFIER", 26, 32], ["grown", "OBSERVATION_MODIFIER", 81, 86]]], ["1 At the current rate of growth, tourist arrivals are expected to top 1.6 billion by the year 2020 ( Fig. 1.2 ).", [["growth", "OBSERVATION_MODIFIER", 25, 31]]], ["1 The market share of international tourism receipts has altered somewhat, though Western European countries, such as France and Spain continue to attract huge numbers of travelers ( Fig. 1.3 ).INTRODUCTIONMore people than ever before are traveling to exotic and remote destinations.", [["people", "ORGANISM", 211, 217], ["people", "SPECIES", 211, 217]]], ["Over centuries of exploration and migration, diseases such as the plague, yellow fever, smallpox, malaria and cholera, and influenza spread around the world through travel.", [["plague", "DISEASE", 66, 72], ["yellow fever", "DISEASE", 74, 86], ["smallpox", "DISEASE", 88, 96], ["malaria", "DISEASE", 98, 105], ["cholera", "DISEASE", 110, 117], ["influenza", "DISEASE", 123, 132], ["yellow fever", "SPECIES", 74, 86], ["exploration", "TREATMENT", 18, 29], ["migration", "TREATMENT", 34, 43], ["diseases", "PROBLEM", 45, 53], ["the plague", "PROBLEM", 62, 72], ["yellow fever", "PROBLEM", 74, 86], ["smallpox", "PROBLEM", 88, 96], ["malaria", "PROBLEM", 98, 105], ["cholera", "PROBLEM", 110, 117], ["influenza", "PROBLEM", 123, 132], ["exploration", "OBSERVATION", 18, 29], ["migration", "OBSERVATION_MODIFIER", 34, 43], ["plague", "OBSERVATION_MODIFIER", 66, 72], ["yellow", "OBSERVATION_MODIFIER", 74, 80], ["fever", "OBSERVATION", 81, 86], ["malaria", "OBSERVATION", 98, 105]]], ["The time to circumnavigate the earth has decreased over the last one and a half centuries, from about 1 year to roughly 36 h -that is, to go from one spot on the globe to any other.", [["earth", "OBSERVATION", 31, 36], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["globe", "ANATOMY", 162, 167]]], ["Although today's travelers are better protected from ancient diseases by better sanitation, immunizations and prophylactic medication, they face the threat of acquiring new, emerging, and re-emerging illnesses such as drug-resistant tuberculosis and malaria, leptospirosis, tick-borne encephalitis, and novel respiratory illnesses such as Severe Acute Respiratory Syndrome (SARS) or even avian influenza (H5N1).", [["respiratory", "ANATOMY", 309, 320], ["tuberculosis", "DISEASE", 233, 245], ["malaria", "DISEASE", 250, 257], ["leptospirosis", "DISEASE", 259, 272], ["tick-borne encephalitis", "DISEASE", 274, 297], ["respiratory illnesses", "DISEASE", 309, 330], ["Acute Respiratory Syndrome", "DISEASE", 346, 372], ["SARS", "DISEASE", 374, 378], ["avian influenza", "DISEASE", 388, 403], ["H5N1", "DISEASE", 405, 409], ["travelers", "ORGANISM", 17, 26], ["avian influenza", "ORGANISM", 388, 403], ["tick-borne encephalitis", "SPECIES", 274, 297], ["avian influenza", "SPECIES", 388, 403], ["tick-borne encephalitis", "SPECIES", 274, 297], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 339, 379], ["ancient diseases", "PROBLEM", 53, 69], ["immunizations", "TREATMENT", 92, 105], ["prophylactic medication", "TREATMENT", 110, 133], ["re-emerging illnesses", "PROBLEM", 188, 209], ["drug-resistant tuberculosis", "PROBLEM", 218, 245], ["malaria", "PROBLEM", 250, 257], ["leptospirosis", "PROBLEM", 259, 272], ["tick-borne encephalitis", "PROBLEM", 274, 297], ["novel respiratory illnesses", "PROBLEM", 303, 330], ["Severe Acute Respiratory Syndrome", "PROBLEM", 339, 372], ["SARS", "PROBLEM", 374, 378], ["even avian influenza (H5N1", "PROBLEM", 383, 409], ["resistant", "OBSERVATION_MODIFIER", 223, 232], ["tuberculosis", "OBSERVATION", 233, 245], ["malaria", "OBSERVATION", 250, 257], ["respiratory illnesses", "OBSERVATION", 309, 330], ["Severe", "OBSERVATION_MODIFIER", 339, 345], ["Acute", "OBSERVATION_MODIFIER", 346, 351], ["Respiratory Syndrome", "OBSERVATION", 352, 372]]], ["2 In addition, and far more important in terms of traveler mortality, is the threat of problems such as injury (due to motor vehicle accidents) or the exacerbation of underlying illness (e.g. cardiac disease).INTRODUCTIONGiven these many challenges, during the 1970s and 1980s several visionary clinicians began exploring the medical requirements and recommendations that would better ensure healthy travel.", [["cardiac", "ANATOMY", 192, 199], ["injury", "DISEASE", 104, 110], ["motor vehicle accidents", "DISEASE", 119, 142], ["cardiac disease", "DISEASE", 192, 207], ["cardiac", "ORGAN", 192, 199], ["injury", "PROBLEM", 104, 110], ["underlying illness", "PROBLEM", 167, 185], ["cardiac disease)", "PROBLEM", 192, 208], ["cardiac", "ANATOMY", 192, 199], ["disease", "OBSERVATION", 200, 207]]], ["This initial exploration into the prevention of travel-related illness has now grown in parallel with the escalation of travel itself, and has become a highly specialized area of medicine devoted to the maintenance of the health of international travelers through health promotion and disease prevention.", [["This initial exploration", "TEST", 0, 24], ["related illness", "PROBLEM", 55, 70], ["disease prevention", "TREATMENT", 285, 303]]], ["It is still a fledgling multidisciplinary field encompassing a wide variety of specialties and subspecialties, including infectious and tropical diseases, public health and preventive medicine, primary care, and geographic, occupational, military, and wilderness medicine.", [["infectious and tropical diseases", "DISEASE", 121, 153], ["infectious and tropical diseases", "PROBLEM", 121, 153], ["preventive medicine", "TREATMENT", 173, 192], ["infectious", "OBSERVATION_MODIFIER", 121, 131], ["tropical diseases", "OBSERVATION", 136, 153]]], ["For some time, travel medicine education has been incorporated into many infectious disease training programs.", [["travel medicine education", "TREATMENT", 15, 40], ["infectious disease training programs", "TREATMENT", 73, 109]]], ["3 Also, travel medicine has broadened to include migration medicine, immigrant health, and has touched on the impact of travel on receiving countries.", [["migration medicine", "TREATMENT", 49, 67]]], ["Unlike many other healthcare specialties, in a number of countries travel medicine is practiced by nurses, pharmacists and physicians alike.INTRODUCTIONThe worldwide focus and knowledge base of travel medicine distinguishes it from other fields of medicine and nursing.", [["travel medicine", "TREATMENT", 194, 209]]], ["Travel medicine practitioners must be aware of infectious disease risks and their magnitude, patterns of drug resistance, current outbreaks of illness, civil and military conflicts, and political barriers to travel at border crossings.", [["illness", "DISEASE", 143, 150], ["drug resistance", "PROBLEM", 105, 120], ["drug resistance", "OBSERVATION", 105, 120]]], ["In addition, they must have access to the most up-to-date information on travel-related vaccines and medications.", [["travel-related vaccines", "TREATMENT", 73, 96], ["medications", "TREATMENT", 101, 112]]], ["For some travel medicine providers, the assessment and management of the ill-returned traveler is an important component of their responsibilities.", [["the assessment", "TEST", 36, 50], ["management", "TREATMENT", 55, 65]]], ["In addition, along with the annual or biennial publication of authoritative information from institutions such as the World Health Organization and the Centers for Disease Control and Prevention (CDC), new global surveillance systems, including GeoSentinel and TropNet Europe, have been developed to track travel-related morbidity, so that all can better understand the emerging health problems related to population movements.", [["Disease Control", "TREATMENT", 164, 179], ["new global surveillance systems", "TEST", 202, 233], ["GeoSentinel", "TREATMENT", 245, 256]]], ["A GeoSentinel review of over 17 000 ill-returned travelers highlighted geographic-specific health risks such as malaria from sub-Saharan Africa, dengue from the Caribbean, Central America and SE Asia, typhoid from South Asia and African tick-typhus from Southern Africa.", [["malaria", "DISEASE", 112, 119], ["sub-Saharan Africa", "DISEASE", 125, 143], ["dengue", "DISEASE", 145, 151], ["SE", "DISEASE", 192, 194], ["typhoid", "DISEASE", 201, 208], ["tick-typhus", "DISEASE", 237, 248], ["tick-typhus", "ORGANISM", 237, 248], ["tick-typhus", "SPECIES", 237, 248], ["African tick-typhus", "SPECIES", 229, 248], ["malaria", "PROBLEM", 112, 119], ["dengue", "PROBLEM", 145, 151], ["typhoid", "PROBLEM", 201, 208], ["African tick", "PROBLEM", 229, 241], ["typhus", "PROBLEM", 242, 248], ["Central", "ANATOMY_MODIFIER", 172, 179], ["typhus", "OBSERVATION", 242, 248]]], ["4 This and follow-up studies have confirmed that compared with the usual tourist, immigrants returning to their places of birth in developing countries, visiting friends and relatives, are at greater risk of malaria, typhoid fever, tuberculosis, intestinal parasites, and sexually transmitted infections.", [["intestinal", "ANATOMY", 246, 256], ["malaria", "DISEASE", 208, 215], ["typhoid fever", "DISEASE", 217, 230], ["tuberculosis", "DISEASE", 232, 244], ["intestinal parasites", "DISEASE", 246, 266], ["sexually transmitted infections", "DISEASE", 272, 303], ["intestinal", "ORGAN", 246, 256], ["follow-up studies", "TEST", 11, 28], ["malaria", "PROBLEM", 208, 215], ["typhoid fever", "PROBLEM", 217, 230], ["tuberculosis", "PROBLEM", 232, 244], ["intestinal parasites", "PROBLEM", 246, 266], ["sexually transmitted infections", "PROBLEM", 272, 303], ["malaria", "OBSERVATION", 208, 215], ["tuberculosis", "OBSERVATION", 232, 244], ["intestinal", "ANATOMY", 246, 256], ["parasites", "OBSERVATION", 257, 266], ["infections", "OBSERVATION", 293, 303]]], ["Today, the focus of travel medicine is on recreational tourists, business persons, overseas volunteers, missionaries, the military, and migrant populations fleeing civil and other conflicts or looking for political asylum or economic opportunities.", [["persons", "SPECIES", 74, 81]]], ["In addition, the current era of the increasing popularity of ecotourism and extreme travel has added a new dimension to the field, including the challenges faced as practitioners counsel increasing numbers of the elderly and the immunocompromised, such as those with HIV, cancer, autoimmune diseases, or organ transplants.", [["cancer", "ANATOMY", 272, 278], ["organ", "ANATOMY", 304, 309], ["cancer", "DISEASE", 272, 278], ["autoimmune diseases", "DISEASE", 280, 299], ["cancer", "CANCER", 272, 278], ["organ", "ORGAN", 304, 309], ["HIV", "SPECIES", 267, 270], ["HIV", "SPECIES", 267, 270], ["ecotourism", "PROBLEM", 61, 71], ["the immunocompromised", "PROBLEM", 225, 246], ["HIV", "PROBLEM", 267, 270], ["cancer", "PROBLEM", 272, 278], ["autoimmune diseases", "PROBLEM", 280, 299], ["organ transplants", "TREATMENT", 304, 321], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["popularity", "OBSERVATION_MODIFIER", 47, 57], ["extreme", "OBSERVATION_MODIFIER", 76, 83], ["immunocompromised", "OBSERVATION", 229, 246], ["cancer", "OBSERVATION", 272, 278]]], ["The complexity and variety of travel itineraries, combined with the many health issues of enthusiastic travelers of all ages, shapes, and sizes, ensure that it takes much longer than appreciated to acquire the expertise necessary to provide travel medicine services.", [["complexity", "OBSERVATION_MODIFIER", 4, 14], ["variety", "OBSERVATION_MODIFIER", 19, 26], ["sizes", "OBSERVATION_MODIFIER", 138, 143]]], ["It is no longer adequate for advice to pass informally from friends, family, or travel counselors to travelers -or even from healthcare specialists in other fields to their patients -warning them only about the potential hazards of tap water!", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["no longer", "UNCERTAINTY", 6, 15]]], ["For example, depending on the study of travelers to malarious areas, only about 50% seek travel health advice, and far fewer are adherent to recommendations for chemoprophylaxis and insect protection.", [["the study", "TEST", 26, 35], ["chemoprophylaxis", "TREATMENT", 161, 177], ["insect protection", "TREATMENT", 182, 199]]], ["[6] [7] [8] Data obtained from the CDC have shown that fewer than one-third of US travelers to areas of the world at risk for yellow fever have received the vaccine (Martin Cetron, personal communication, 2002).", [["yellow fever", "DISEASE", 126, 138], ["yellow fever", "PROBLEM", 126, 138]]], ["In addition, similar studies in several different countries show that travelers often seek their pretravel health advice at the last minute, if at all.", [["travelers", "ORGANISM", 70, 79], ["similar studies", "TEST", 13, 28]]], ["The chapters in this textbook address the most important issues in this rapidly growing and ever changing field, and represent an important step in the education of all travel medicine providers.Middle East 2%South Asia 1%Middle East 2%Africa 3%Middle East 2%Americas 26%Middle East 2%East Asia and the Pacific 18% Europe 50% Available: http://www.world-tourism.org/facts/menu.html (accessed May", [["Middle East", "TREATMENT", 195, 206], ["the Pacific", "TREATMENT", 299, 310]]]], "003fa21e67f7d722d463135f354d23db0229de7e": [], "PMC7185842": [["Simian foamy viruses in humansSince the initial description of foamy virus (FV) in rhesus monkey kidney cells in 1954 [3], such viruses have been isolated from several animal species, including numerous NHP species.", [["kidney cells", "ANATOMY", 97, 109], ["Simian foamy viruses", "DISEASE", 0, 20], ["Simian foamy viruses", "ORGANISM", 0, 20], ["humans", "ORGANISM", 24, 30], ["foamy virus", "ORGANISM", 63, 74], ["FV", "ORGANISM", 76, 78], ["rhesus", "ORGANISM", 83, 89], ["monkey", "ORGANISM", 90, 96], ["kidney cells", "CELL", 97, 109], ["1954 [3]", "CELL", 113, 121], ["NHP", "ORGANISM", 203, 206], ["rhesus monkey kidney cells", "CELL_TYPE", 83, 109], ["Simian", "SPECIES", 0, 6], ["humans", "SPECIES", 24, 30], ["rhesus monkey", "SPECIES", 83, 96], ["Simian foamy viruses", "SPECIES", 0, 20], ["humans", "SPECIES", 24, 30], ["foamy virus", "SPECIES", 63, 74], ["FV", "SPECIES", 76, 78], ["rhesus monkey", "SPECIES", 83, 96], ["Simian foamy viruses", "PROBLEM", 0, 20], ["foamy virus", "PROBLEM", 63, 74], ["kidney cells", "TEST", 97, 109], ["such viruses", "PROBLEM", 123, 135], ["several animal species", "PROBLEM", 160, 182], ["numerous NHP species", "PROBLEM", 194, 214], ["foamy viruses", "OBSERVATION", 7, 20], ["foamy virus", "OBSERVATION", 63, 74], ["several", "OBSERVATION_MODIFIER", 160, 167], ["animal species", "OBSERVATION", 168, 182], ["numerous", "OBSERVATION_MODIFIER", 194, 202], ["NHP species", "OBSERVATION", 203, 214]]], ["The prevalence of FVs in naturally infected animals is generally high, but varies widely according to species [2].", [["FVs", "CHEMICAL", 18, 21], ["naturally infected", "DISEASE", 25, 43], ["FVs", "GENE_OR_GENE_PRODUCT", 18, 21], ["naturally", "OBSERVATION_MODIFIER", 25, 34], ["infected", "OBSERVATION", 35, 43], ["generally", "OBSERVATION_MODIFIER", 55, 64], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["Among NHP populations, SFV seroprevalence can reach up to 75\u2013100% in adults [2].", [["SFV", "ORGANISM", 23, 26], ["SFV", "SPECIES", 23, 26]]], ["In African green monkey and macaques, oral mucosa tissue is an important site for viral replication, explaining why foamy viral RNA is found at a high concentration in the saliva of such primates [4\u2022\u2022].", [["oral mucosa tissue", "ANATOMY", 38, 56], ["green monkey", "ORGANISM", 11, 23], ["macaques", "ORGANISM", 28, 36], ["oral mucosa tissue", "TISSUE", 38, 56], ["foamy viral", "ORGANISM", 116, 127], ["saliva", "ORGANISM_SUBSTANCE", 172, 178], ["foamy viral RNA", "RNA", 116, 131], ["green monkey", "SPECIES", 11, 23], ["macaques", "SPECIES", 28, 36], ["African green monkey", "SPECIES", 3, 23], ["oral mucosa tissue", "PROBLEM", 38, 56], ["viral replication", "TREATMENT", 82, 99], ["foamy viral RNA", "PROBLEM", 116, 131], ["green monkey", "OBSERVATION", 11, 23]]], ["Saliva-based means of transmission, such as bites, have been thus strongly suggested.", [["Saliva", "ORGANISM_SUBSTANCE", 0, 6]]], ["Infection by SFV itself does not seem to cause any disease in infected NHPs, but studies have not been conducted to address this question specifically.", [["SFV", "ORGANISM", 13, 16], ["NHPs", "ORGANISM", 71, 75], ["SFV", "SPECIES", 13, 16], ["Infection", "PROBLEM", 0, 9], ["any disease in infected NHPs", "PROBLEM", 47, 75], ["SFV", "OBSERVATION", 13, 16], ["not seem to cause", "UNCERTAINTY", 29, 46], ["disease", "OBSERVATION", 51, 58], ["infected", "OBSERVATION", 62, 70]]], ["However, when considering co-infections in macaques, SFV can increase the pathogenicity of simian immunodeficiency virus [5].Simian foamy viruses in humansIn 1971, the first human foamy virus was isolated from the cell culture of a Kenyan patient suffering of nasopharyngeal carcinoma [6].", [["cell", "ANATOMY", 214, 218], ["nasopharyngeal carcinoma", "ANATOMY", 260, 284], ["simian immunodeficiency virus", "DISEASE", 91, 120], ["Simian foamy viruses", "DISEASE", 125, 145], ["nasopharyngeal carcinoma", "DISEASE", 260, 284], ["macaques", "ORGANISM", 43, 51], ["SFV", "ORGANISM", 53, 56], ["simian immunodeficiency virus", "ORGANISM", 91, 120], ["Simian foamy viruses", "ORGANISM", 125, 145], ["humansIn 1971", "CELL", 149, 162], ["human", "ORGANISM", 174, 179], ["foamy virus", "ORGANISM", 180, 191], ["cell", "CELL", 214, 218], ["patient", "ORGANISM", 239, 246], ["nasopharyngeal carcinoma", "CANCER", 260, 284], ["macaques", "SPECIES", 43, 51], ["simian immunodeficiency virus", "SPECIES", 91, 120], ["Simian", "SPECIES", 125, 131], ["human", "SPECIES", 174, 179], ["patient", "SPECIES", 239, 246], ["macaques", "SPECIES", 43, 51], ["SFV", "SPECIES", 53, 56], ["simian immunodeficiency virus", "SPECIES", 91, 120], ["Simian foamy viruses", "SPECIES", 125, 145], ["human foamy virus", "SPECIES", 174, 191], ["co-infections in macaques", "PROBLEM", 26, 51], ["SFV", "PROBLEM", 53, 56], ["simian immunodeficiency virus", "PROBLEM", 91, 120], ["Simian foamy viruses", "PROBLEM", 125, 145], ["the first human foamy virus", "PROBLEM", 164, 191], ["the cell culture", "TEST", 210, 226], ["nasopharyngeal carcinoma", "PROBLEM", 260, 284], ["simian immunodeficiency", "OBSERVATION", 91, 114], ["foamy viruses", "OBSERVATION", 132, 145], ["nasopharyngeal", "ANATOMY", 260, 274], ["carcinoma", "OBSERVATION", 275, 284]]], ["Phylogenetic studies demonstrated that this virus originated from the East African chimpanzee subspecies (Pan troglodytes schweinfurtii).", [["chimpanzee", "ORGANISM", 83, 93], ["Pan troglodytes schweinfurtii", "ORGANISM", 106, 135], ["chimpanzee subspecies", "SPECIES", 83, 104], ["Pan troglodytes", "SPECIES", 106, 121], ["schweinfurtii", "SPECIES", 122, 135], ["African chimpanzee", "SPECIES", 75, 93], ["Pan troglodytes schweinfurtii", "SPECIES", 106, 135], ["Phylogenetic studies", "TEST", 0, 20], ["this virus", "PROBLEM", 39, 49], ["Pan troglodytes schweinfurtii", "TREATMENT", 106, 135]]], ["This strain is now considered to be the \u2018prototype foamy virus\u2019 (PFV).", [["foamy virus", "ORGANISM", 51, 62], ["PFV", "ORGANISM", 65, 68], ["PFV", "SPECIES", 65, 68], ["This strain", "PROBLEM", 0, 11]]], ["However, its exact origin remains unclear (in vivo cross-species transmission from a chimpanzee to the African patient, or cell culture contamination) [7].", [["cell", "ANATOMY", 123, 127], ["chimpanzee", "ORGANISM", 85, 95], ["patient", "ORGANISM", 111, 118], ["cell", "CELL", 123, 127], ["patient", "SPECIES", 111, 118], ["cell culture contamination", "TEST", 123, 149]]], ["In the 1970/80s, several papers showed conflicting results on the presence of SFV in human populations and in different patients [8, 9].", [["SFV", "ORGANISM", 78, 81], ["human", "ORGANISM", 85, 90], ["patients", "ORGANISM", 120, 128], ["human", "SPECIES", 85, 90], ["patients", "SPECIES", 120, 128], ["SFV", "SPECIES", 78, 81], ["human", "SPECIES", 85, 90], ["SFV in human populations", "PROBLEM", 78, 102], ["SFV", "OBSERVATION", 78, 81]]], ["These findings reflected the high percentage of non-specific serological reactivity and the lack of specific confirmatory tests at that time.Simian foamy viruses in humansIn 1995, based on specific serological and molecular assays, the first clear evidence of SFV in Humans was reported among 3 laboratory and monkey house personnel [10\u2022\u2022].", [["Simian foamy viruses", "DISEASE", 141, 161], ["Simian foamy viruses", "ORGANISM", 141, 161], ["humans", "ORGANISM", 165, 171], ["SFV", "ORGANISM", 260, 263], ["Humans", "ORGANISM", 267, 273], ["monkey", "ORGANISM", 310, 316], ["Simian", "SPECIES", 141, 147], ["humans", "SPECIES", 165, 171], ["Simian foamy viruses", "SPECIES", 141, 161], ["humans", "SPECIES", 165, 171], ["SFV", "SPECIES", 260, 263], ["non-specific serological reactivity", "PROBLEM", 48, 83], ["specific confirmatory tests", "TEST", 100, 127], ["Simian foamy viruses in humans", "PROBLEM", 141, 171], ["specific serological", "TEST", 189, 209], ["molecular assays", "TEST", 214, 230], ["SFV", "PROBLEM", 260, 263], ["high", "OBSERVATION_MODIFIER", 29, 33], ["percentage", "OBSERVATION_MODIFIER", 34, 44], ["non-specific", "OBSERVATION_MODIFIER", 48, 60], ["serological reactivity", "OBSERVATION", 61, 83], ["foamy viruses", "OBSERVATION", 148, 161], ["SFV", "OBSERVATION", 260, 263]]], ["Since then, other groups have reported similar findings in a series of workers occupationally exposed to NHPs in the USA and Canada and more recently in personnel from zoos or primate centers in Gabon and China [8].", [["NHPs", "ORGANISM", 105, 109]]], ["Infection by SFV in a more natural setting was then demonstrated in villagers from Cameroon [11].", [["SFV", "ORGANISM", 13, 16], ["SFV", "SPECIES", 13, 16], ["Infection", "PROBLEM", 0, 9], ["SFV", "PROBLEM", 13, 16], ["SFV", "OBSERVATION_MODIFIER", 13, 16]]], ["They were mostly hunters who reported direct contacts with blood and/or body fluids from wild NHPs.", [["blood", "ANATOMY", 59, 64], ["body fluids", "ANATOMY", 72, 83], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["fluids", "ORGANISM_SUBSTANCE", 77, 83], ["NHPs", "ORGANISM", 94, 98], ["blood and/or body fluids", "TREATMENT", 59, 83]]], ["We extended such studies into different areas and populations of this Central African country and found the presence of SFV infection in at least 50 persons [12\u2022\u2022].", [["infection", "DISEASE", 124, 133], ["SFV", "ORGANISM", 120, 123], ["persons", "SPECIES", 149, 156], ["SFV", "SPECIES", 120, 123], ["such studies", "TEST", 12, 24], ["SFV infection", "PROBLEM", 120, 133], ["SFV", "OBSERVATION_MODIFIER", 120, 123], ["infection", "OBSERVATION", 124, 133]]], ["The great majority of them (Bantus or Pygmies) were men who had been bitten by an ape (mostly gorillas but also chimpanzees) or a small monkey (mostly Cercopithecus nictitans) during hunting activities.", [["men", "ORGANISM", 52, 55], ["chimpanzees", "ORGANISM", 112, 123], ["monkey", "ORGANISM", 136, 142], ["Cercopithecus nictitans", "ORGANISM", 151, 174], ["men", "SPECIES", 52, 55], ["monkey", "SPECIES", 136, 142], ["Cercopithecus nictitans", "SPECIES", 151, 174], ["Cercopithecus nictitans", "SPECIES", 151, 174], ["great", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18], ["small", "OBSERVATION_MODIFIER", 130, 135]]], ["A recent report from Gabon confirmed such frequent cross-species transmission in hunters after severe bites from mostly gorilla [13].", [["severe bites", "PROBLEM", 95, 107]]], ["Infected women were also recently found in the Democratic Republic of Congo [14].", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14]]], ["In South and Southeast Asian countries, SFV zoonotic infection has also been detected in various contexts of interspecies contact including \u2018monkey temple\u2019 workers, pet owners and people living around free-ranging macaques in South and Southeast Asia [15].", [["zoonotic infection", "DISEASE", 44, 62], ["SFV", "ORGANISM", 40, 43], ["monkey", "ORGANISM", 141, 147], ["people", "ORGANISM", 180, 186], ["macaques", "ORGANISM", 214, 222], ["monkey", "SPECIES", 141, 147], ["people", "SPECIES", 180, 186], ["SFV", "SPECIES", 40, 43], ["SFV zoonotic infection", "PROBLEM", 40, 62]]], ["It is interesting to note that the Human/NHP interface in Asia differs greatly from that in Africa [16].", [["Human", "ORGANISM", 35, 40], ["NHP", "ORGANISM", 41, 44], ["Human", "SPECIES", 35, 40]]], ["Human and macaques sympatry in Southeast Asia dates back as far as 25,000 years.", [["Human", "ORGANISM", 0, 5], ["macaques", "ORGANISM", 10, 18], ["Human", "SPECIES", 0, 5], ["macaques", "SPECIES", 10, 18]]], ["Human-macaque commensalism is frequent in many monkey temples of these regions each year putting a very large number of persons, including tourists, at risk for macaques bites [17].", [["Human-macaque commensalism", "DISEASE", 0, 26], ["Human", "ORGANISM", 0, 5], ["macaque", "ORGANISM", 6, 13], ["monkey", "ORGANISM", 47, 53], ["persons", "ORGANISM", 120, 127], ["macaques", "ORGANISM", 161, 169], ["Human", "SPECIES", 0, 5], ["-macaque", "SPECIES", 5, 13], ["persons", "SPECIES", 120, 127], ["Human-macaque", "SPECIES", 0, 13]]], ["Indeed, human subjects in some South Asian countries came into contact with rhesus macaques mostly in the context of their daily lives, sharing a geographical area that is the \u2018home range\u2019 of both primate populations [16].", [["human", "ORGANISM", 8, 13], ["rhesus", "ORGANISM", 76, 82], ["macaques", "ORGANISM", 83, 91], ["human", "SPECIES", 8, 13], ["rhesus macaques", "SPECIES", 76, 91], ["human", "SPECIES", 8, 13], ["rhesus macaques", "SPECIES", 76, 91]]], ["Such frequent interactions can lead to possible viral interspecies transmission.", [["viral interspecies transmission", "PROBLEM", 48, 79]]], ["The situation is very different in central Africa where bush-meat hunting (including Apes such as gorillas and chimpanzees) is the major risk factor associated with SFV interspecies transmission [12\u2022\u2022].", [["meat", "ORGANISM_SUBDIVISION", 61, 65], ["chimpanzees", "ORGANISM", 111, 122], ["SFV", "ORGANISM", 165, 168], ["SFV", "SPECIES", 165, 168], ["very", "OBSERVATION_MODIFIER", 17, 21], ["different", "OBSERVATION_MODIFIER", 22, 31], ["central", "OBSERVATION_MODIFIER", 35, 42], ["Africa", "OBSERVATION_MODIFIER", 43, 49]]], ["Furthermore, in Central Africa, the number of contacts between humans (mostly hunters and their wives and butchers) and potentially infected NHPs has probably greatly increased during the last century.", [["humans", "ORGANISM", 63, 69], ["NHPs", "ORGANISM", 141, 145], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["Central", "OBSERVATION_MODIFIER", 16, 23], ["Africa", "OBSERVATION_MODIFIER", 24, 30], ["infected", "OBSERVATION", 132, 140], ["probably", "UNCERTAINTY", 150, 158], ["greatly", "OBSERVATION_MODIFIER", 159, 166], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["This is believed to be due to increased hunting activities, resulting from a combination of urban demand for bush-meat, greater access to NHP habitats provided in part by logging roads, easier accessibility to fire arms, an increase in populations living in forest areas, and the associated increase in local food needs [2].Simian foamy viruses in humansWhile nowadays, Humans are not considered to be a natural host of SFV, more than 100 cases of SFV infection have been reported so far in individuals in close contact with NHPs [8].", [["Simian foamy viruses", "DISEASE", 324, 344], ["SFV infection", "DISEASE", 448, 461], ["Simian foamy viruses", "ORGANISM", 324, 344], ["humans", "ORGANISM", 348, 354], ["Humans", "ORGANISM", 370, 376], ["SFV", "ORGANISM", 420, 423], ["SFV", "ORGANISM", 448, 451], ["Simian", "SPECIES", 324, 330], ["humans", "SPECIES", 348, 354], ["Simian foamy viruses", "SPECIES", 324, 344], ["humans", "SPECIES", 348, 354], ["SFV", "SPECIES", 420, 423], ["SFV", "SPECIES", 448, 451], ["increased hunting activities", "PROBLEM", 30, 58], ["urban demand", "TREATMENT", 92, 104], ["NHP habitats", "TREATMENT", 138, 150], ["Simian foamy viruses in humans", "PROBLEM", 324, 354], ["SFV infection", "PROBLEM", 448, 461], ["believed to be due to", "UNCERTAINTY", 8, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["hunting", "OBSERVATION", 40, 47], ["increase", "OBSERVATION_MODIFIER", 224, 232], ["increase", "OBSERVATION_MODIFIER", 291, 299], ["foamy viruses", "OBSERVATION", 331, 344], ["SFV", "OBSERVATION_MODIFIER", 448, 451], ["infection", "OBSERVATION", 452, 461]]], ["Among them, no specific pathology has been yet demonstrated.", [["specific pathology", "PROBLEM", 15, 33], ["no", "UNCERTAINTY", 12, 14], ["specific", "OBSERVATION_MODIFIER", 15, 23], ["pathology", "OBSERVATION", 24, 33]]], ["However, the selection bias inherent in the enrollment of healthy persons in the very few performed studies greatly limits the current ability to identify any potential associated disease.SFV genomic organization and structural proteinsThe SFV genome comprises the retroviral gag, pol and env genes, and two regulatory genes tas and bet.", [["SFV", "ORGANISM", 188, 191], ["SFV", "ORGANISM", 240, 243], ["retroviral", "ORGANISM", 265, 275], ["gag", "GENE_OR_GENE_PRODUCT", 276, 279], ["pol", "GENE_OR_GENE_PRODUCT", 281, 284], ["env", "GENE_OR_GENE_PRODUCT", 289, 292], ["bet", "GENE_OR_GENE_PRODUCT", 333, 336], ["structural proteins", "PROTEIN", 217, 236], ["SFV genome", "DNA", 240, 250], ["retroviral gag, pol and env genes", "DNA", 265, 298], ["regulatory genes", "DNA", 308, 324], ["tas", "DNA", 325, 328], ["bet", "DNA", 333, 336], ["persons", "SPECIES", 66, 73], ["SFV", "SPECIES", 188, 191], ["SFV", "SPECIES", 240, 243], ["any potential associated disease", "PROBLEM", 155, 187], ["SFV genomic organization", "PROBLEM", 188, 212], ["structural proteins", "PROBLEM", 217, 236], ["disease", "OBSERVATION", 180, 187], ["genomic organization", "OBSERVATION", 192, 212], ["structural proteins", "OBSERVATION", 217, 236], ["SFV genome", "OBSERVATION", 240, 250], ["retroviral gag", "OBSERVATION", 265, 279], ["env genes", "OBSERVATION", 289, 298]]], ["An internal promoter allows basal transcription of tas and bet (Figure 1).", [["internal promoter", "DNA", 3, 20], ["tas", "PROTEIN", 51, 54], ["bet", "PROTEIN", 59, 62], ["An internal promoter", "TREATMENT", 0, 20], ["tas and bet (Figure", "TREATMENT", 51, 70]]], ["The transactivator Tas then activates a second promoter located in the long-terminal repeat, which induces the synthesis of the Gag, Pol and Env structural proteins.", [["long-terminal repeat", "ANATOMY", 71, 91], ["Tas", "GENE_OR_GENE_PRODUCT", 19, 22], ["long-terminal repeat", "CELLULAR_COMPONENT", 71, 91], ["Gag", "GENE_OR_GENE_PRODUCT", 128, 131], ["Pol", "GENE_OR_GENE_PRODUCT", 133, 136], ["Env structural proteins", "GENE_OR_GENE_PRODUCT", 141, 164], ["Tas", "PROTEIN", 19, 22], ["long-terminal repeat", "DNA", 71, 91], ["Gag", "PROTEIN", 128, 131], ["Pol", "PROTEIN", 133, 136], ["Env structural proteins", "PROTEIN", 141, 164], ["a second promoter", "TREATMENT", 38, 55]]], ["SFVs can also go through a late reverse transcription step, before the release of SFV particles.", [["SFVs", "SIMPLE_CHEMICAL", 0, 4], ["SFV", "ORGANISM", 82, 85], ["SFV", "SPECIES", 82, 85], ["SFV particles", "OBSERVATION", 82, 95]]], ["Thus, SFV particles can contain SFV RNA and SFV DNA genomes (Figure 2A) [18].SFV tropism", [["SFV", "ORGANISM", 6, 9], ["SFV", "ORGANISM", 32, 35], ["SFV", "ORGANISM", 44, 47], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["SFV", "ORGANISM", 77, 80], ["SFV RNA", "RNA", 32, 39], ["SFV DNA genomes", "DNA", 44, 59], ["SFV", "SPECIES", 6, 9], ["SFV", "SPECIES", 32, 35], ["SFV", "SPECIES", 44, 47], ["SFV", "SPECIES", 77, 80], ["SFV particles", "TREATMENT", 6, 19], ["SFV RNA", "TREATMENT", 32, 39], ["SFV tropism", "PROBLEM", 77, 88], ["SFV particles", "OBSERVATION", 6, 19], ["SFV RNA", "OBSERVATION", 32, 39], ["tropism", "OBSERVATION", 81, 88]]]]}